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Abstract
A randomised controlled trial to compare the safety,
effectiveness and cost-effectiveness of doxycycline
(200 mg/day) with that of oral prednisolone (0.5 mg/kg/day)
for initial treatment of bullous pemphigoid: the Bullous
Pemphigoid Steroids and Tetracyclines (BLISTER) trial
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Background: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with increased morbidity
and mortality in the elderly.
Objectives: To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP
treatment with oral doxycycline or oral prednisolone. We hypothesised that starting treatment with
doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over
starting treatment with oral prednisolone.
Design: Pragmatic multicentre two-armed parallel-group randomised controlled trial with an
economic evaluation.
Setting: A total of 54 dermatology secondary care centres in the UK and seven in Germany.
Participants: Adults with BP [three or more blisters at two sites and positive direct and/or indirect
immunofluorescence (immunoglobulin G and/or complement component 3 immunofluorescence at the
dermal-epidermal junction)] and able to give informed consent.
Interventions: Participants were allocated using online randomisation to initial doxycycline treatment
(200 mg/day) or prednisolone (0.5 mg/kg/day). Up to 30 g/week of potent topical corticosteroids was
permitted for weeks 1–3. After 6 weeks, clinicians could switch treatments or alter the prednisolone dose
as per normal practice.
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Main outcome measures: Primary outcomes: (1) the proportion of participants with three or fewer
blisters at 6 weeks (investigator blinded) and (2) the proportion with severe, life-threatening and fatal
treatment-related events at 52 weeks. A regression model was used in the analysis adjusting for baseline
disease severity, age and Karnofsky score, with missing data imputed. Secondary outcomes included the
effectiveness of blister control after 6 weeks, relapses, related adverse events and quality of life. The
economic evaluation involved bivariate regression of costs and quality-adjusted life-years (QALYs) from a
NHS perspective.
Results: In total, 132 patients were randomised to doxycycline and 121 to prednisolone. The mean patient
age was 77.7 years and baseline severity was as follows: mild 31.6% (three to nine blisters), moderate
39.1% (10–30 blisters) and severe 29.3% (> 30 blisters). For those starting on doxycycline, 83 out of 112
(74.1%) had three or fewer blisters at 6 weeks, whereas for those starting on prednisolone 92 out of 101
(91.1%) had three or fewer blisters at 6 weeks, an adjusted difference of 18.6% in favour of prednisolone
[90% confidence interval (CI) 11.1% to 26.1%], using a modified intention-to-treat (mITT) analysis.
Per-protocol analysis showed similar results: 74.4% compared with 92.3%, an adjusted difference of 18.7%
(90% CI 9.8% to 27.6%). The rate of related severe, life-threatening and fatal events at 52 weeks was
18.2% for those started on doxycycline and 36.6% for those started on prednisolone (mITT analysis), an
adjusted difference of 19.0% (95% CI 7.9% to 30.1%; p = 0.001) in favour of doxycycline. Secondary
outcomes showed consistent findings. There was no significant difference in costs or QALYs per patient at
1 year between doxycycline-initiated therapy and prednisolone-initiated therapy (incremental cost of
doxycycline-initiated therapy £959, 95% CI –£24 to £1941; incremental QALYs of doxycycline-initiated
therapy –0.024, 95% CI –0.088 to 0.041). Using a willingness-to-pay criterion of < £20,000 per QALY
gained, the net monetary benefit associated with doxycycline-initiated therapy was negative but imprecise
(–£1432, 95% CI –£3094 to £230).
Conclusions: A strategy of starting BP patients on doxycycline is non-inferior to standard treatment with oral
prednisolone for short-term blister control and considerably safer in the long term. The limitations of the trial
were the wide non-inferiority margin, the moderate dropout rate and that serious adverse event collection was
unblinded. Future work might include inducing remission with topical or oral corticosteroids and then
randomising to doxycycline or prednisolone for maintenance.
Trial registration: Current Controlled Trials ISRCTN13704604.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 10.
See the NIHR Journals Library website for further project information.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Contents
List of tables xiii
List of figures xvii
Glossary xix
List of abbreviations xxi
Plain English summary xxiii
Scientific summary xxv
Chapter 1 Introduction 1
Background 1
What is pemphigoid? 1
Increased mortality 1
Topical treatment 2
Rationale for testing tetracyclines further 2
Chapter 2 Methods 3
Trial design 3
Choice of intervention 3
Rescue medication 3
Choice of tetracycline 3
Trial outcomes 4
Primary outcomes 4
Secondary outcomes 4
Tertiary outcomes 5
Participants 5
Retention of participants 5
Withdrawal of participants 5
Informed consent 6
Recruitment 6
Randomisation 6
Blinding 6
Sample size 7
Analysis 7
Subgroup analyses 8
Cost-effectiveness 8
The EuroQoL tool 8
Resource use 8
Economic analysis 9
Chapter 3 Results 11
Study population 11
Baseline characteristics 11
Withdrawals 13
Adherence to interventions for primary effectiveness at 6 weeks 13
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ix
Primary outcomes 13
Primary effectiveness outcome 13
Subgroup analyses 18
Primary safety outcome 21
Secondary outcomes 22
Secondary effectiveness outcome: weeks 6, 13 and 52 22
Secondary outcome: relapse rates 27
Secondary outcome: combined outcome of effectiveness at 6 weeks and safety over
52 weeks 28
Secondary safety outcome: all adverse events 28
Secondary outcome: quality of life 29
Tertiary outcomes 30
Tertiary effectiveness outcome: proportion of participants who achieved treatment
success at 3 weeks (non-inferiority) 31
Tertiary safety outcome: mortality over the 52-week follow-up period (superiority) 33
Tertiary effectiveness outcome: use of potent and superpotent topical corticosteroids
during the 52-week follow-up period (superiority) 34
Additional post-hoc analysis 35
Post-hoc analysis: primary effectiveness outcome repeated at week 52 35
Post-hoc analysis: action (treatment changes) taken in response to relapse 35
Post-hoc analysis: time to switching treatment 36
Post-hoc analysis: sensitivity of the primary effectiveness outcome at 6 weeks to
topical corticosteroid use 37
Post-hoc analysis: safety data at 52 weeks according to baseline disease severity 38
Chapter 4 Cost-effectiveness 39
Objective 39
Overview 39
Methods 39
Data sources 39
Multiple imputation 40
Incremental analysis 41
Uncertainty 41
Results 42
Completeness of data 42
Complete-case estimates 42
Cost-effectiveness analysis 45
Sensitivity and subgroup analyses 47
Other quality-of-life measures 48
Conclusion 48
Chapter 5 Discussion 51
Main findings 51
Cost-effectiveness 52
How our evidence fits with existing evidence 52
Strengths and limitations 53
Strengths 53
Limitations 54
Implications for practice 56
Implications for research 56
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
x
Chapter 6 Conclusions 59
Acknowledgements 61
References 63
Appendix 1 Survey results 67
Appendix 2 Health economics analysis plan 69
Appendix 3 Reasons for exclusion from the per-protocol analyses 75
Appendix 4 Trial oversight committees 79
Appendix 5 Trial management team 81
Appendix 6 Recruiting centres 83
Appendix 7 Data collection tools 87
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi

List of tables
TABLE 1 Numbers of participants randomised to each arm and reasons
for ineligibility 13
TABLE 2 Baseline characteristics 14
TABLE 3 Numbers of participants withdrawn from the trial and the primary reasons 15
TABLE 4 Numbers of participants withdrawn from the trial by each visit 15
TABLE 5 Cumulative number of participants withdrawn from the trial 16
TABLE 6 Adherence prior to week 6 17
TABLE 7 Proportions of participants who achieved treatment success at 6 weeks:
mITT analysis 17
TABLE 8 Proportions of participants who achieved treatment success at 6 weeks:
PP analysis 18
TABLE 9 Subgroup analysis of baseline disease severity and treatment effect:
mITT analysis 19
TABLE 10 Subgroup analysis of baseline disease severity and treatment effect:
PP analysis 20
TABLE 11 Subgroup analysis of blinding status and treatment effect: mITT analysis 20
TABLE 12 Subgroup analysis of blinding status and treatment effect: PP analysis 20
TABLE 13 Proportions of participants experiencing at least one adverse event of
grade 3 or higher that was possibly, probably or definitely related to study
treatment (raw data set): mITT analysis 21
TABLE 14 Proportions of participants experiencing at least one adverse event of
grade 3 or higher that was possibly, probably or definitely related to study
treatment (with imputed data): mITT analysis 21
TABLE 15 The maximum grade of adverse event that each participant
experienced during the trial that was considered possibly, probably or definitely
related to the study drug: mITT analysis 22
TABLE 16 Total number of grade 3, 4 and 5 related adverse events: mITT analysis 22
TABLE 17 Proportions of participants who achieved treatment success at
6 weeks: mITT analysis 23
TABLE 18 Proportions of participants who achieved treatment success at
6 weeks: PP analysis 23
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii
TABLE 19 Subgroup analysis of baseline disease severity and the proportion of
participants who achieved treatment success at 6 weeks: mITT analysis 24
TABLE 20 Subgroup analysis of baseline disease severity and the proportion of
participants who achieved treatment success at 6 weeks: PP analysis 24
TABLE 21 Subgroup analysis of baseline blinding status and the proportion of
participants who achieved treatment success at 6 weeks: mITT analysis 25
TABLE 22 Subgroup analysis of baseline blinding status and the proportion of
participants who achieved treatment success at 6 weeks: PP analysis 25
TABLE 23 Proportions of participants who achieved treatment success at
13 weeks: mITT analysis 25
TABLE 24 Proportions of participants who achieved treatment success at
13 weeks: PP analysis 26
TABLE 25 Proportions of participants who achieved treatment success at
52 weeks: mITT analysis 26
TABLE 26 Proportions of participants who achieved treatment success at
52 weeks: PP analysis 27
TABLE 27 Proportions of participants who had a further episode of BP after
previously being classified as a treatment success: mITT analysis 27
TABLE 28 Proportions of participants who had a further episode of BP after
previously being classified as a treatment success: PP analysis 28
TABLE 29 Proportions of patients who were classed as a treatment success at
6 weeks and were alive at 52 weeks 28
TABLE 30 The maximum grade of adverse event that each participant
experienced during the trial that was considered possibly, probably or definitely
related to the study drug (any grade): raw data 29
TABLE 31 Proportions of patients with any related adverse event during the
trial: mITT analysis 29
TABLE 32 Total number of related adverse events by grade: raw data 30
TABLE 33 Difference in EQ-5D scores (raw data): mITT analysis 30
TABLE 34 Difference in EQ-5D scores: mITT analysis 31
TABLE 35 Difference in DLQI scores (raw data): mITT analysis 31
TABLE 36 Difference in DLQI scores: mITT analysis 31
TABLE 37 Proportions of participants who were completely blister free at
week 6: mITT analysis 32
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
TABLE 38 Number of patients in the mITT population excluded from the PP analysis 32
TABLE 39 Proportions of participants who were completely blister free at
week 6: PP analysis 32
TABLE 40 Proportions of participants who achieved treatment success at
3 weeks: mITT analysis 33
TABLE 41 Proportions of participants who achieved treatment success at
3 weeks: PP analysis 33
TABLE 42 Mortality over the 52-week follow-up period: mITT analysis 34
TABLE 43 All-cause mortality: mITT analysis 34
TABLE 44 Potent and superpotent topical corticosteroid use according to study
period and treatment allocation 35
TABLE 45 Proportions of participants who achieved treatment success at
52 weeks: mITT analysis 35
TABLE 46 Proportions of participants who achieved treatment success at
52 weeks: PP analysis 36
TABLE 47 Action taken in response to disease relapse 36
TABLE 48 Proportions of participants who achieved treatment success at
6 weeks: PP analysis using any topical corticosteroid use in weeks 3–6 as a
reason for exclusion from the PP analysis population 37
TABLE 49 Participants reporting an adverse event of at least grade 3 that is
possibly, probably or definitely related to BP medication in the 52 weeks
following randomisation (raw data) 38
TABLE 50 Unit costs applied to patient resource use (2013 cost base) 40
TABLE 51 Base-case and sensitivity analyses 42
TABLE 52 Completeness of data by follow-up visit 43
TABLE 53 Health status scores: complete cases 43
TABLE 54 Resource use: complete cases 44
TABLE 55 Costs: complete cases (£, 2013) 44
TABLE 56 Cost-effectiveness analysis (£, 2013) 46
TABLE 57 EuroQol visual analogue scale and DLQI AUC estimates 48
TABLE 58 Reasons for exclusion from the primary efficacy analysis at week 6 75
TABLE 59 Reasons for exclusion from the secondary efficacy analysis at week 6 75
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv
TABLE 60 Reasons for exclusion from the secondary efficacy analysis at week 13 75
TABLE 61 Reasons for exclusion from the secondary efficacy analysis at week 52 76
TABLE 62 Reasons for exclusion from the secondary analysis of the proportion of
participants who have a further episode of BP during their participation in the
study after previously being classified as a treatment success 76
TABLE 63 Reasons for exclusion from the tertiary analysis of the proportion of
participants classed as a treatment success at week 3 76
TABLE 64 Reasons for exclusion from the tertiary analysis of the proportion of
participants who achieved treatment success at 52 weeks 77
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xvi
List of figures
FIGURE 1 Large tense blisters and erosions in a man with BP (by kind permission
of Professor Enno Schmidt with written consent from the patient) 1
FIGURE 2 Recruitment graph 11
FIGURE 3 Consolidated Standards of Reporting Trials flow chart 12
FIGURE 4 Kaplan–Meier survival plot showing time to withdrawal
(including death) 17
FIGURE 5 Proportions of participants who achieved treatment success at
6 weeks: mITT and PP analyses 18
FIGURE 6 Kaplan–Meier survival plot showing time to death 34
FIGURE 7 Kaplan–Meier survival plot showing time to change of treatment 37
FIGURE 8 Cost-effectiveness plane: base-case analysis [cost per QALY (£), 2013] 45
FIGURE 9 Cost-effectiveness acceptability curve: base-case analysis –
doxycycline-initiated therapy 47
FIGURE 10 Relationship between net monetary benefit and willingness to pay
for doxycycline-initiated treatment 47
FIGURE 11 Cost-effectiveness plane: subgroup analysis [cost per QALY (£), 2013] 48
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xvii

Glossary
Blinding/masking Procedures designed to ensure that those assessing outcomes in a study are not aware
of the treatment allocations.
Bullous pemphigoid An autoimmune blistering skin disease.
Intention to treat The principle of including all those originally randomised in the final analysis.
Non-inferiority comparison An approach to hypothesis testing that sets out to show that a treatment is
acceptably inferior to another treatment within a predefined acceptability margin.
Per protocol A form of analysis that evaluates only those participants who adhered strictly to the
study protocol.
Skin immunofluorescence A technique for detecting whether or not circulating autoantibodies are
present in the skin. In pemphigoid, these are found at the junction between the epidermis and the dermis.
Superiority comparison An approach to hypothesis testing that sets out to show that one treatment is
superior to another by a defined margin.
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Plain English summary
Bullous pemphigoid (BP) is an uncommon itchy blistering skin problem that is more common in old age.Steroid tablets are often used to clear up blisters quickly in people with BP, but they can lead to serious
side effects such as diabetes, infections and fractures. Antibiotics such as doxycycline are used to treat BP
and, although less effective at controlling blisters quickly, they might be safer than steroids over a long
period. We set out to compare the benefits and harms of these two treatments. We split 253 people with
BP into two similar groups randomly (by chance), starting one group on doxycycline tablets (200 mg daily)
and the other group on oral steroids at a daily dose of 0.5 mg/kg of body weight. People could switch
from one treatment to another or change the dose after 6 weeks as advised by their doctor. In terms of
early control, 74.1% in the doxycycline group had three or fewer blisters at 6 weeks, compared with
91.1% in the steroid group. When we looked at harms, 18.2% of those starting on doxycycline had
severe, life-threatening or fatal outcomes within the 1-year follow-up period compared with 36.3% of
those on steroids. The results were about the same for people who had mild, moderate or severe BP. We
conclude that a policy of starting treatment with doxycycline is reasonably effective in the short term and
much safer than starting treatment with oral steroids in the long term.
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Scientific summary
Background
Bullous pemphigoid (BP) is an autoimmune disease characterised by antibodies directed at the junction
between the dermis and the epidermis. Large, tense blisters form as a result, some of which break down
to form open sore areas that can become infected. The blisters and surrounding skin can be very itchy,
leading to poor quality of life. BP is more common in older people and seems to be on the increase. It is
also associated with neurological conditions, such as dementia and stroke, and with increased mortality in
general. Previous studies have shown that potent topical corticosteroids applied to the whole skin surface
can be used for treating BP successfully, but this is often not practical in an elderly outpatient population.
Oral steroids are still the most commonly used treatment for BP in the UK. Although some dermatologists
have used tetracycline antibiotics to treat BP, a Cochrane systematic review concluded that their effects
have not been well tested. It is unlikely that tetracyclines would be more effective than oral steroids, yet
they are likely to be safer given the problems associated with long-term use of oral steroids in the elderly,
such as diabetes, fractures and serious infections. We therefore sought to see whether or not a strategy of
starting treatment of BP with tetracyclines still produces an acceptable degree of short-term blister control
compared with starting on oral corticosteroids (a non-inferiority comparison), while at the same time
conferring a long-term advantage over oral corticosteroids in terms of safety (a superiority comparison).
Methods
Trial perspective
This was a pragmatic, two-arm, parallel, multicentre randomised controlled clinical trial of 52 weeks’
duration comparing a strategy of starting people with BP on 200 mg of doxycycline daily with a strategy of
starting people with BP on 0.5 mg/kg/day of oral prednisolone.
Participants
Adults presenting to secondary dermatological care with a clinical diagnosis of BP with at least three
significant blisters or erosions in the last week on at least two body sites and who were able to give
informed consent were eligible. In addition, eligible patients had to have positive direct or indirect (serum)
immunofluorescence (immunoglobulin G and/or complement component 3 at the epidermal basement
membrane zone) to confirm the clinical diagnosis. Patients must have been free of blisters and treatment
for previous episodes of BP in the preceding year. Those already on systemic medications for their BP,
or those taking either study medication for other reasons in the 12 weeks before the study, were excluded,
as were those with mostly or entirely mucosal pemphigoid.
Interventions
This study compared a strategy of initiating treatment with 200 mg daily of doxycycline with a strategy of
initiating treatment with 0.5 mg/kg/day of oral prednisolone. Investigators were encouraged to keep the
dose fixed for the first 6-week blinded phase to assess short-term blister control, but after this point
treatments could be adjusted, switched or changed according to treatment response, as would occur in
typical clinical practice. Participants were allowed to use up to 30 g per week of a potent topical
corticosteroid (mometasone furoate) on affected areas for the first 3 weeks of treatment only and then
again after the 6-week blister count to reflect normal UK practice.
Trial outcomes
Our two primary outcomes were (1) the proportion of patients with three or fewer blisters at 6 weeks
(short-term effectiveness – a non-inferiority comparison) and (2) the proportion of patients with
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medication-related severe, life-threatening or fatal adverse events at 52 weeks (long-term safety outcome –
a superiority comparison). Secondary outcomes included the effectiveness of blister control after 6 weeks,
relapse rates, related adverse events of all grades, quality of life and cost-effectiveness.
Randomisation and masking (blinding)
Randomisation was based on a computer-generated pseudorandom code using random permuted blocks
of randomly varying size, created by the Nottingham Clinical Trials Unit. Randomisation was stratified by
initial disease severity and concealed from investigators for the initial 6 weeks of treatment. Investigators
were blinded to treatment allocation when blister counts were assessed at 6 weeks. Investigators were
unblinded after this point to enable medication to be adjusted to reflect normal clinical practice. Participants
were not blinded to study medications. Collection of adverse events after 6 weeks was not blinded, but the
relatedness of all serious adverse events and deaths was judged by an independent adjudicator.
Sample size
We expected that around 60% of patients starting on oral prednisolone would eventually experience a
severe, life-threatening or fatal drug-related adverse event by 52 weeks. To demonstrate at least a 20%
reduction in such harms for those initiated on doxycycline, we estimated that 256 patients would be needed
(80% power at the 5% significance level and a 1 : 1 allocation), assuming a 20% loss to follow-up at 1 year.
Assuming that the ‘success rate’ of three or fewer blisters at 6 weeks would be around 95% in the group
started on oral prednisolone and 70% in the group started on doxycycline, an absolute difference of 25%.
The acceptable non-inferiority margin was set at 37% based on the upper bound of the 90% confidence
interval (CI) for this difference. Allowing for 5% loss to follow-up at 6 weeks, a total of 234 participants were
required at 80% power for such a non-inferiority margin. Analysis for the superiority safety outcomes was on
an intention-to-treat (ITT) basis. Analysis of the non-inferiority effectiveness comparison included both an ITT
and a per-protocol (PP) analysis. Analysis was conducted using a regression model, adjusting for baseline
severity of BP, age and Karnofsky score, and missing data were imputed.
Monitoring and ethics
Trial oversight was by a Trial Steering Committee and an independent Data Monitoring Committee.
Ethics permission was granted for all participating sites.
Results
Numbers randomised and baseline characteristics
In total, 278 participants were randomised from 54 UK and seven German dermatology centres, with
25 withdrawn because of ineligibility (n = 19 negative immunofluorescence, n = 1 too few blisters,
n = 1 uncertain clinical diagnosis and n = 4 other reasons), leaving a total of 253 eligible randomised
participants. Overall, 53% of the trial population were men and 47% were women and most (84%) were
white. The age distribution of participants was as follows: ≥ 85 years, 25%; 75 to < 85 years, 38%; 65 to
< 75 years, 28%; and < 65 years, 10%. Around 29% of participants had severe disease (> 30 blisters),
39% moderate disease (10–30 blisters) and 32% mild disease (three to nine blisters). Baseline
characteristics (age, sex, ethnicity, BP severity, Karnofsky score of functional impairment) were well
matched between the two groups. The proportion who withdrew or died was 13.0% at 6 weeks and
36.4% at 52 weeks.
Effectiveness outcomes
For the primary effectiveness outcome of three or fewer blisters at 6 weeks, 91.1% of those randomised
to prednisolone achieved success compared with 74.1% of those randomised to doxycycline using a
modified intention-to-treat (mITT) analysis, a difference of 18.6% (90% CI 11.1% to 26.1%) in favour
of prednisolone. A PP analysis showed a similar result, with 92.3% and 74.4% achieving success in the
prednisolone and doxycycline groups, respectively, a difference of 18.7% (90% CI 9.8% to 27.6%). There
was no evidence to support a difference in effectiveness according to baseline disease severity (p-values
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for an interaction test on the mITT population for severe and moderate compared with mild disease at
baseline of 0.863 and 0.417 respectively). The proportions achieving treatment success at 13 weeks were
75.3% and 58.6% in the prednisolone and doxycycline groups, respectively, a difference of 17.5%
(90% CI 6.8% to 28.2%) in favour of prednisolone. Corresponding values for treatment success at
52 weeks were 51.1% and 41.0% for prednisolone and doxycycline, respectively, a difference of 10.0%
(90% CI –2.3% to 22.2%) in favour of prednisolone. Relapse rates were similar in the prednisolone and
doxycycline groups (35.8% and 32.5%, respectively, a difference of 2.1%, 90% CI –0.83% to 12.5%).
Safety outcomes
Using a mITT analysis, related severe, life-threatening and fatal events by 52 weeks were experienced by
36.3% and 18.2% of those started on prednisolone and doxycycline, respectively, an adjusted difference of
19.0% (95% CI 7.9% to 30.1%; p = 0.001). When estimated from an adjusted regression model on a data
set where missing data were imputed using multiple imputation there was a difference of 18.4% (95% CI
6.0% to 30.8%; p = 0.004) in favour of doxycycline. Total adverse events (including mild and moderate)
were similar between the two treatment strategy groups (95.7% and 86.2% in the prednisolone and
doxycycline groups respectively). There were 11 treatment-related deaths in the prednisolone treatment
strategy group compared with three in the doxycycline treatment strategy group.
Quality of life and cost-effectiveness
Quality of life improved in both groups. The European Quality of Life-5 Dimensions (EQ-5D) showed a
difference of 0.045 (95% CI –0.015 to 0.106; p = 0.143) between the prednisolone treatment strategy
and the doxycycline treatment strategy after adjusting for baseline EQ-5D score, baseline severity, age and
Karnofsky score. A similar difference was seen in the Dermatology Life Quality Index scores.
There was no significant difference in costs or quality-adjusted life-years (QALYs) gained comparing the two
strategies. Using imputed data for the base-case analysis, after 1 year of treatment the incremental cost of
doxycycline-initiated therapy was £959 per patient (95% CI –£24 to £1941), whereas the average quality
of life decrement was –0.024 QALYs (95% CI –0.088 to 0.041 QALYs). Using a willingness-to-pay criterion
of < £20,000 per QALY gained, the net monetary benefit (NMB) associated with doxycycline-initiated
therapy was negative if imprecise (NMB –£1432, 95% CI –£3094 to £230). However, subgroup analysis
indicated that for patients presenting with severe blisters doxycycline-initiated therapy was not cost-effective
(NMB –£4361, 95% CI –£8283 to –£439), whereas patients presenting with mild or moderate blisters had
very similar costs and outcomes at 1 year (NMB –£251, 95% CI –£1987 to £1485). Resources displaced in
the NHS by doxycycline-initiated therapy may be greater than the value of benefit gained in the severe
blister patient subgroup. Economic model findings were robust under extensive sensitivity analyses.
Conclusions
Main findings
This pragmatic study shows that a strategy of starting people with BP on 200 mg daily of oral doxycycline
is safer by a considerable margin than a strategy of starting them on oral prednisolone. These long-term
gains in safety were at the expense of short-term compromises in effectiveness, but these fell well
within our prespecified non-inferiority margin. There was a suggestion that the relative effectiveness
of prednisolone compared with doxycycline varied according to blister severity at baseline, but these
differences did not reach statistical significance in our planned subgroup analysis. The overall pattern of
treatment differences between the two strategies was consistent throughout the duration of the trial and
did not change when tested against a range of sensitivity analyses. It is important to realise that the
differences between the two treatment groups reflect the overall strategy of initiating treatment with
doxycycline or prednisolone, rather than a strict comparison of one drug against the other. Such a strategy
permits switching medicines or adjusting doses over the 52-week period as might occur in routine
clinical practice.
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Strengths and limitations
Study strengths included the large sample size and the fact that participants were representative of those
presenting to secondary dermatological care and came from a wide geographical area in two countries;
the pragmatic nature of the study, which allowed for dose adjustment and medication switches to match
everyday clinical practice; and the rigour in ensuring concealed allocation and blinded assessment of the
effectiveness outcome. Study limitations included the exclusion of patients with dementia on ethical
grounds and losses to follow-up for longer-term outcomes.
Clinical and research implications
This study has confirmed for the first time that doxycycline does have a useful effect in controlling BP
blisters and also that oral prednisolone at a dose of 0.5 mg/kg/day is very effective, albeit at the expense of
significant related serious, life-threatening and fatal adverse events. In people with BP in whom extensive
application of topical corticosteroids is not practical, a strategy of starting patients on oral doxycycline plus
local application of topical corticosteroids to affected areas may be considered in preference to the current
standard UK practice of starting BP patients on oral prednisolone. The estimates of the trade-off between
reduced short-term effectiveness and increased long-term safety gains for doxycycline-initiated treatment
obtained from this study now provide clear data to inform shared decision-making between health-care
professionals and patients/carers over BP treatment choices. Because doxycycline may have a slower
beneficial effect on blister control than prednisolone, future research might consider a study whereby all
patients with BP are brought into rapid remission with a short course of potent topical corticosteroids or
low-dose oral steroids and are then randomised to maintenance treatment for a year with either oral
doxycycline or continuation with oral corticosteroids.
Trial registration
This trial is registered as ISRCTN13704604.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
What is pemphigoid?
Bullous pemphigoid (BP) is the most common form of a group of autoimmune pemphigoid diseases
characterised by autoantibodies directed at skin adhesion proteins of the epidermal–dermal junction.1
BP often starts with intense itching followed by an urticated and/or eczematous-looking rash and tense
blisters on erythematous or normal-looking skin (Figure 1). The blisters may develop several months after
the appearance of the initial symptoms and may be quite large and filled with blood. They often break
down to form raw skin erosions, which can become infected.
The pain and severe itching associated with BP can greatly impair quality of life. BP typically affects people
aged around 80 years and the incidence, which appears to be on the increase, is estimated to be between
6 and 43 cases per million per year.2,3 The cause of BP is unknown but it is associated with neurological
conditions such as cerebrovascular disease, dementia, Parkinson’s disease, epilepsy and multiple sclerosis4,5
and the chronic use of several drugs including spironolactone (Aldactone®, Pharmacia Ltd), neuroleptics,
certain diuretics and phenothiazines in some patients.4,6–9 Neurological disease has been suggested as a
predisposing and prognostic factor.10
Increased mortality
Mortality rates are increased for people with BP. In one study the risk of death was more than six times
that of the general population.11 Mortality rates for people with BP of between 11% and 41% have
been suggested to be related to advanced age and comorbid medical conditions rather than the disease
itself.12,13 It is likely that the increase in mortality rate is owing, at least in part, to side effects of oral
prednisolone, which is commonly used to treat BP.14–17
FIGURE 1 Large tense blisters and erosions in a man with BP (by kind permission of Professor Enno Schmidt
with written consent from the patient).
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Topical treatment
Some widely reported studies have shown that superpotent topical corticosteroids applied to the whole
skin surface are effective and safer than oral corticosteroids.18,19 Practical guidance on how this can be
carried out is provided elsewhere.15 However, the application of topical steroids to the whole body for
weeks or possibly months is not a practical option in many elderly outpatients with limited support.
Therefore, there still remains a need for a convenient oral treatment that is both effective and safe.
Rationale for testing tetracyclines further
Treatment of BP with antibiotics possessing anti-inflammatory actions, such as those from the tetracycline
group, is widely used in clinical practice. In a national survey of 326 UK dermatologists conducted in 2013,
around 80% stated that they had used doxycycline (Efracea®, Galderma), minocycline (Aknemin®, Almirall
Hermal GmbH) or lymecycline (Tetralysal®, Galderma).20 However, a Cochrane systematic review21 found
only one small poorly reported clinical trial22 and concluded that further evidence was needed before the
effectiveness of tetracyclines could be established. No further trials of tetracyclines were identified in a
subsequent systematic review23 nor in a search of the Cochrane Central Register of Controlled Trials using
‘pemphigoid’ as a search term (28 May 2015). The limited data available and practical experience to date
suggest that it is very unlikely that tetracyclines would be more effective than long-term use of oral
corticosteroids, yet they are likely to be safer in this elderly population given the known adverse effects of
oral corticosteroids, including diabetes mellitus, serious infections and osteoporosis, leading to fractures
and death. Because some patients with BP might not respond to tetracyclines at all, it was clearly
important to test how they might be used in clinical practice by permitting additional application of
potent topical corticosteroids to affected areas or a switch to oral corticosteroids if symptoms and blister
control were inadequate. Similarly, in the UK, those initiated on oral steroids are typically given topical
corticosteroids for localised application to blisters to help with initial control and doses of oral
corticosteroids are typically adjusted over several months, according to blister control or side effects. We
therefore sought to investigate whether or not a strategy of initial treatment of BP with anti-inflammatory
tetracyclines (200 mg/day of doxycycline) is effective enough to produce an acceptable degree of blister
control compared with initial treatment with oral corticosteroids (0.5 mg/kg/day of prednisolone) in a
non-inferiority comparison and whether or not tetracyclines confer a long-term advantage in terms of
safety over oral corticosteroids in a superiority comparison.
INTRODUCTION
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Chapter 2 Methods
Parts of this report are based on Williams et al.24 This article is published open access under the terms ofthe Creative Commons Attribution 4.0 licence (CC-BY) (https://creativecommons.org/licenses/by/4.0).
Trial design
The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial was a two-arm, parallel-group,
multicentre, multinational randomised controlled trial of 52 weeks’ duration. The design was towards the
pragmatic end of the explanatory–pragmatic spectrum.25 We recruited patients with BP from the UK
and Germany who had not started systemic treatment. Participants were randomised to receive either
doxycycline or prednisolone as initial treatment and were followed up at weeks 3, 6, 13, 26, 39 and 52,
with unscheduled visits as required to reflect normal clinical care.
The two primary outcomes in this trial reflect the need for patients and clinicians to balance the likely
differences in effectiveness and safety for oral prednisolone and doxycycline when making a shared
decision on treatment. Although topical corticosteroids have been shown to be effective for BP, it is not
always practical or cost-effective to admit elderly people into hospital for whole body application15 and
therefore oral treatment alternatives are needed. Although oral prednisolone is thought to be effective
at reducing the blisters in BP, it has many side effects as indicated in previous trials comparing topical
corticosteroids with oral corticosteroids.18,19,26 Doxycycline, on the other hand, is perceived to be less
effective by clinicians but probably has fewer side effects. Therefore, a non-inferiority comparison was used
to assess effectiveness, the results of which could be considered alongside the superiority comparison of
safety in clinical decision-making.
The trial protocol was published prior to the analysis.27
Choice of intervention
At baseline, patients were randomised to receive either 0.5mg/kg/day of prednisolone or 200mg/day of
doxycycline, both taken as a single, daily dose (brand not specified). We chose a starting dose of 0.5 mg/kg/day
for prednisolone based on safety concerns over higher doses such as 0.75–1mg/kg/day highlighted in the
Cochrane systematic review.22 The study protocol encouraged investigators to stick to the allocated treatment
and dose for the first 6 weeks unless it was medically necessary to change, but after the 6-week effectiveness
assessment investigators were free to modify the dose as needed, switch to the other treatment arm or
administer an alternative treatment if appropriate, to reflect normal clinical practice. Participants were followed
up for the full 52 weeks when possible, regardless of any changes to treatment. Participants recorded study
medication use in their diary.
Rescue medication
Up to 30 g/week of topical corticosteroids in the potent class [preferably mometasone furoate (Elocon®,
Merck Sharp & Dohme Ltd)] was permitted throughout the study, except between weeks 3 and 6. The
cessation of topical corticosteroids from week 3 to week 6 provided a washout period to minimise the
potential effect of systemic absorption of topical corticosteroids on the primary effectiveness outcome at
6 weeks. To minimise potential systemic effects, topical corticosteroids were applied only to blisters and
erosions. Participants were permitted to apply a moisturiser to blisters and erosions at any time.
Choice of tetracycline
Doxycycline was chosen for this trial because (1) it is associated with a lower incidence of gastrointestinal
side effects than other tetracyclines and (2) the alternative option of oxytetracycline would have required
participants to swallow approximately eight large tablets a day.
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Although the only published randomised controlled trial investigating tetracycline antibiotics for the
treatment of BP used a combination therapy of tetracycline plus nicotinamide,21 a single therapy of
doxycycline was chosen for this trial to allow the effects of the tetracycline to be clearly defined.
Trial outcomes
We did not identify any core outcome sets for BP when this study was designed, although some consensus
criteria have subsequently been suggested by an international group.28
Primary outcomes
The primary outcomes were the absolute difference between the two treatment arms in the:
l Non-inferiority comparison. The proportion of participants classed as a treatment success (three or
fewer significant blisters present on examination) at 6 weeks. A significant blister was defined as an
intact fluid-filled blister at least 5 mm in diameter or a ruptured blister with a flexible (not dry) roof over
a moist base. Mucosal blisters were excluded from the count.
l Superiority comparison. The proportion of participants with grade 3 (severe), 4 (life-threatening) and
5 (death) adverse events that were possibly, probably or definitely related to the treatment in the
52 weeks following randomisation. A modified version of the Common Terminology Criteria for Adverse
Events v3.0 was used [see http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/
ctcaev3.pdf (accessed 12 November 2015)] and the relatedness of grade 5 (fatal) adverse events was
judged by an independent adjudicator. Although only grade 3 and above related adverse events were
captured in the primary outcome, less medically important related adverse events (such as weight
gain and skin fragility) can bother patients when taking corticosteroids and so were included in a
secondary outcome.
For the primary outcome, treatment success was defined as three or fewer significant blisters, regardless of
whether or not treatment had been modified because of a poor response (either by changing the dose or
by changing the treatment) during the first 6 weeks. However, for all secondary and tertiary end points,
participants were classed as a treatment success at each visit only if (1) they had three or fewer significant
blisters present on examination and (2) their treatment had not been altered because of a poor response
prior to that visit.
Secondary outcomes
The secondary outcomes were the absolute difference between the two treatment arms in the following:
l non-inferiority comparisons:
¢ proportion of participants classed as a treatment success (three or fewer significant blisters present
on examination and no treatment modification) at 6 weeks
¢ proportion of participants classed as a treatment success at 13 and 52 weeks
¢ proportion of participants who had a further episode of BP during the study
l superiority comparisons:
¢ proportion of participants reporting adverse events of any grade that were possibly, probably or
definitely related to BP medication in the 52 weeks following randomisation
¢ quality of life [European Quality of Life-5 Dimension (EQ-5D) and Dermatology Life Quality Index
(DLQI) questionnaires at 6, 13, 26, 39 and 52 weeks]
¢ cost-effectiveness over 12 months from a NHS perspective
l combined comparison: proportion of participants classed as a treatment success at 6 weeks and who
were alive at 52 weeks.
METHODS
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Tertiary outcomes
The tertiary outcomes were the absolute difference between the two treatment arms in the following:
l non-inferiority comparisons:
¢ proportion of participants completely blister free at 6 weeks
¢ proportion of participants classed as a treatment success at 3 weeks (to compare the speed of
onset of action)
l superiority comparisons:
¢ mortality over the 52-week follow-up period
¢ amount of potent and superpotent topical corticosteroids used during the 52 weeks
following randomisation.
Participants
Adults (aged ≥ 18 years) who were capable of giving written informed consent and who had a clinical
diagnosis of BP were eligible. To ensure that active disease was present, at least three significant blisters
(defined as intact, fluid-filled blisters measuring ≥ 5 mm) must have appeared within the week prior to
screening and must have been present across at least two body sites. Recent erosions could be included
provided that they had a flexible (not dry) roof over a moist base. Positive direct (skin biopsy) or indirect
(serum) immunofluorescence [immunoglobulin G (IgG) and/or complement component 3 (C3) at the
epidermal basement membrane zone) was required to confirm diagnosis. Anonymised samples were tested
at the Immunofluorescence Laboratory at the Department of Dermatology, John Radcliffe Hospital, Oxford,
and the Institute of Dermatology Immunodermatology Laboratory at St John’s Institute of Dermatology,
St Thomas’s Hospital, London. Samples with appropriately obtained consent were sent to the Clinical
Immunological Laboratory, University of Lübeck, Germany, for additional immunology substudies, which
will be published separately.
Patients must have been free of blisters and have not received treatment for previous episodes of BP in the
preceding year. Patients were excluded if they had predominantly mucosal pemphigoid, had received any
systemic medication for the current episode of BP or had received oral prednisolone or doxycycline for any
other conditions in the preceding 12 weeks. Women of childbearing potential who were not taking
adequate contraception, as well as those who were pregnant or who planned to become pregnant during
the study or who were currently lactating, were excluded. Additional exclusions for safety reasons were live
virus vaccine administration within the previous 3 months, allergy to any member of the tetracycline family
or a pre-existing condition or use of a medication that precluded the use of either study drug or that made
the patient unsuitable for this trial, as assessed by the investigator.
Retention of participants
To help retain participants in the study, in addition to being able to speak to the investigator, participants
were able to telephone the trial manager if they wished to discuss any aspect of the study. For medical
queries, participants were directed to a medical member of staff. In addition, the trial administrator made
telephone calls to participants to support them throughout the duration of the study. Participants were
sent birthday and Christmas cards while they were participating in the study.
Withdrawal of participants
Patients whose immunofluorescence test results were not available until after randomisation and which
were subsequently both negative, indicating that they did not have BP, were withdrawn from the trial,
replaced and not included in the analysis. This approach reflects normal practice: if there is a clinical
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picture of BP, treatment is commenced and this is changed later if the laboratory tests are
subsequently negative.
Participants who withdrew from study treatment were followed up for the remainder of the year unless
they had withdrawn their consent.
Informed consent
Patients presenting with suspected BP were assessed by the recruiting investigator as per normal clinical
practice. If a diagnosis of BP was suspected, the patient was given details of the study verbally. If the
patient was interested in taking part he or she was given time to read the full participant information
leaflet and the investigator answered any questions. A consent form was signed before any study
procedures were carried out.
If the disease severity was such that immediate oral treatment was required or the patient did not wish to
delay the start of treatment, he or she was able to give consent and be randomised to the study during
the first visit to the dermatologist. Otherwise, the patient was given a second appointment for consent
and randomisation.
Recruitment
To meet the target for this rare disease, recruitment took place at a large number of hospitals, mainly in
dermatology clinics (54 in the UK and seven in Germany).
Randomisation
Randomisation was based on a computer-generated pseudorandom code using random permuted blocks
of randomly varying size, created by the Nottingham Clinical Trials Unit (NCTU) in accordance with its
standard operating procedure and held on a secure server. Access to the sequence during the trial was
confined to the NCTU data manager.
Participants were allocated in a 1 : 1 ratio to the doxycycline and prednisolone treatment arms.
Randomisation was stratified by disease severity, which was defined as the number of blisters present at
baseline (mild: 1–9; moderate: 10–30; severe: > 30).
The investigator or research nurse randomised participants using the web-based NCTU randomisation
system. The treatment allocation was sent directly to the pharmacist who dispensed the appropriate
medication directly, which allowed the investigator to remain blinded.
Blinding
Investigators (outcome assessors) were unaware of treatment allocation and remained blinded to
treatment allocation for the first 6 weeks of the trial. At the week 6 visit, the investigators carried out the
blister count (primary effectiveness outcome) while blinded to treatment allocation. The investigators were
unblinded for the remaining assessments: that is, for the primary safety outcome (adverse events over
the full 52 weeks) and the long-term effectiveness outcomes. Unblinding before the 6-week point was
permitted if required for treatment decisions that affected patient safety. Investigators were asked at
week 6 if they were aware of the treatment allocation prior to carrying out the blister count for the
primary effectiveness outcome to capture the rate of unblinding. A subgroup analysis to assess any
potential bias of unblinding on the blister count at 6 weeks was performed. The patients and pharmacists
were not blinded to treatment allocation.
METHODS
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Sample size
In total, 256 participants were needed to detect a clinically important absolute difference of 20% in grade 3,
4 and 5 (mortality) side effects within 1 year of randomisation (primary safety outcome). This was based on an
expected 60% incidence with prednisolone compared with 40% with doxycycline29 with 80% power at the
5% significance level allowing for a 20% loss to follow-up by 1 year using a 1 : 1 allocation ratio. A survey of
UK dermatologists showed that a 20% absolute reduction in side effects was considered to be an acceptable
and worthwhile clinical difference. More detailed results can be found in Appendix 1.
The effectiveness outcome at 6 weeks was expressed as a two-sided 90% confidence interval (CI) for the
absolute difference in success rates (based on blister count) between the prednisolone (control) arm and the
doxycycline (intervention) arm. It was assumed that the point estimate for this difference would be 25%,
based on an expected response rate of 95% in the control (prednisolone) arm and 70% in the intervention
(doxycycline) arm. The acceptable non-inferiority margin was set at 37% based on the upper bound of the
90% CI for an expected 25% difference. Because the non-inferiority margin is inversely proportional to
the sample size, the number of patients who we could realistically expect to recruit in a rare disease of the
elderly was factored in when setting the non-inferiority margin. The closer to the expected difference of
25% we set the non-inferiority margin, the larger the sample size that would be required. With 80%
power, a total of 111 evaluable participants per group was required. The attrition rate in the initial 6 weeks
was expected to be low (5%) and so a total of 234 participants was required, that is, within the 256
required for the primary safety outcome.
Analysis
All superiority analyses were conducted on a modified intention-to-treat (mITT) basis and all non-inferiority
analyses were performed on both the mITT and the per-protocol (PP) population according to
recommended practice.30
The mITT population consisted of those participants who fulfilled the eligibility criteria, who were
randomised to receive either study drug and who had data on the outcome of interest.
For each non-inferiority outcome, the doxycycline arm was considered to be non-inferior to the
prednisolone arm if the upper bound of the CI for the difference in proportions was less than the agreed
non-inferiority margin of an absolute difference of 37% in both the mITT and the PP analyses.
All analyses were adjusted for baseline disease severity to optimise power and reduce possible imbalances
in possible response predictors. Age and Karnofsky score31 were also adjusted for in analyses as continuous
variables when possible using a binomial regression with identity links. Methods for dealing with missing
data can be found in the statistical analysis plan [see www.nottingham.ac.uk/research/groups/cebd/
projects/5rareandother/index.aspx (accessed 19 May 2015)]. Multiple imputation was used to handle
missing data because of missed visits for the primary safety analysis.
Patients were excluded from the PP analysis of the primary outcome if, before their 6-week visit, for
reasons other than treatment success or failure, they had:
l increased the dose of their allocated treatment
l changed treatment or added a new treatment to their allocated treatment (for a reason other than for
treatment failure or success)
l used topical steroids between visit weeks 3 and 6
l missed more than 3 consecutive days of treatment.
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For non-inferiority outcomes after week 6, the PP populations consisted of those participants who were
included in the PP analysis of the 6-week primary effectiveness outcome and who had:
l not missed more than 3 consecutive weeks of allocated treatment between 6 and 52 weeks
(regardless of whether the dose had been increased or decreased) unless they had stopped for good
clinical response
l used no more than 30 g of topical steroids per week after week 6
l not added systemic steroids to doxycycline (if allocated) or doxycycline or an immunosuppressant to
prednisolone (if allocated) unless for poor clinical response.
For the non-inferiority outcomes, 90% CIs are presented. For the study treatment doxycycline to be
considered non-inferior to the control treatment, the upper bound of the 90% CI should fall below 37%.
For the superiority outcomes, 95% CIs are presented. A difference between treatment arms was
considered statistically significant at the 5% level, that is, the 95% CIs do not contain zero (no difference
between arms).
The primary analysis had a dual outcome, one primary outcome for effectiveness and one for safety.
For the study treatment doxycycline to be considered acceptable as an alternative to prednisolone,
non-inferiority had to be demonstrated (as defined above) with regard to effectiveness, as well as the
superiority of doxycycline over prednisolone for safety.
Subgroup analyses
For some patients the blister count at 6 weeks may have been performed by an investigator who knew
what treatment the patient was on. To determine whether or not this introduced bias into the results of
the 6-week effectiveness outcome, an interaction test was performed to compare the treatment effects in
patients who were and patients who were not assessed by an investigator who knew the treatment
allocation. This interaction analysis was performed on both the primary and the secondary definition of
treatment success at 6 weeks.
Subgroup analyses of treatment success (using both definitions) at 6 weeks by the three categories of
baseline disease severity (mild, moderate and severe) were also performed. A global test for a treatment
interaction was used to determine whether or not treatment effects were different in the three categories
of disease severity.
Cost-effectiveness
The EuroQoL tool
The EuroQol tool is a two-page questionnaire consisting of the EQ-5D descriptive system and the EuroQol
visual analogue scale (EQ VAS).32 The tool is a standardised measure of current health status developed by
the EuroQol group for clinical and economic studies. The EQ-5D three-level version (EQ-5D-3L) was used,
consisting of five questions addressing the health dimensions of mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. Each dimension is assessed at three levels: no problems, some
problems and extreme problems. EQ-5D and EQ VAS data were collected using patient-completed
questionnaires at baseline and 6, 13, 26, 39 and 52 weeks. Scores were converted to a single health-related
index ranging from 0 (death) to 1 (perfect health), with negative scores possible for some health states.
Patients who died during the study were subsequently scored 0 at later scheduled follow-up visits.
Resource use
Resource use assessments were carried out at 3, 6, 13, 26, 39 and 52 weeks during mandatory clinical
visits and were augmented by telephone calls. Recall was assisted by the use of patient diaries. Patients’
use of study and non-study drugs was recorded and costed using weighted average prices determined
from Prescription Cost Analysis (PCA) data.33 Health service contacts were recorded by asking patients to
METHODS
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recall general practitioner (GP) clinic and home visits, practice and district nurse visits, outpatient visits
and inpatient stays. Health-care resource use was costed using published national reference costs.34–36
Patient-level resource costs were estimated as the sum of resources used weighted by their national
reference costs.
Economic analysis
The economic analysis followed intention-to-treat (ITT) principles and a prospectively agreed analysis plan
(see Appendix 2). No discounting was applied to economic data reflecting the follow-up period of 1 year.
Costs were estimated in UK pounds sterling using patient resource use and 2013 reference costs.35
The analysis took an English NHS perspective, reporting generic (EQ-5D, EQ VAS)32 and disease-specific
(DLQI)37 health outcomes. Repeated scores over time were used to construct area under the curve (AUC)
estimates for each patient, using the trapezoidal method. Missing values at individual follow-up points
were managed using two scenarios: multiple imputation (the base-case analysis38) and analysis of complete
cases (in which patients with any missing data were excluded).
Patient estimates of costs and quality-adjusted life-years (QALYs) at 1 year were used to derive an estimate
of the cost-effectiveness of doxycycline-initiated therapy compared with prednisolone-initiated therapy for
patients with BP. Estimates using imputed missing data provided the base-case analysis and estimates
using complete data provided supportive sensitivity analysis. Analysis and modelling were undertaken in
Stata 13 (StataCorp, College Station, TX, USA). The base-case analysis included the imputed within-trial
incremental cost/QALYs gained, adjusted for trial covariates (age, sex, baseline blister severity and baseline
Karnofsky score). QALY estimates were also adjusted for baseline EQ-5D score.
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Chapter 3 Results
Study population
Recruitment commenced in March 2009 in the UK and in February 2010 in Germany and was completed
in October 2013. In total, 278 patients were randomised from 54 centres in the UK and seven centres in
Germany (Figure 2).
Of the 1604 patients screened for eligibility, 1326 were excluded, mainly because of an inability to provide
informed consent, frailty or their disease being too mild or because they had already been started on
prednisolone by their GP (Figure 3). Of the 278 patients randomised, 140 were allocated to the doxycycline
arm and 138 to the prednisolone arm (Table 1). However, 19 patients were excluded because both the
direct and the indirect immunofluorescence tests were negative and a further six were excluded for other
eligibility reasons. Therefore, 253 patients were included in the analyses, 132 in the doxycycline arm and
121 in the prednisolone arm (see Figure 3).
Baseline characteristics
Of the 253 eligible patients randomised, 52.6% were men and 47.4% were women. The average age was
77.7 years, with 25.3% aged > 85 years, 37.9% aged from 75 to < 85 years, 28.1% aged from 65 to
< 75 years and 8.7% aged < 65 years. There was a good distribution of baseline severity of disease:
29.3% of patients had severe BP (> 30 blisters), 39.1% had moderate disease (10–30 blisters) and 31.6%
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FIGURE 2 Recruitment graph.
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Assessed for eligibility
(n = 1604)
Randomised
(n = 278)
Eligible
(n = 253)
Allocated to doxycycline (n = 132) Allocated to prednisolone (n = 121)
Excluded (n = 1326)
• Fewer than three blisters or fewer 
   than two body sites, n = 157
• Controlled by topical therapy, n = 75
• Already on trial medications, n = 486
• Significant comorbidities, n = 145
• Refused to consent, n = 98
• Unable to give consent/dementia, 
   n = 162
• Other (e.g. pregnant, lives too 
   far away, language barrier), n = 166
• No reason given, n = 37
Excluded (n = 25)
• Both immunofluorescence tests 
   negative, n = 19
• Uncertainty about diagnosis or need
   for treatment, n = 1
• Insufficient number of blisters, n = 1
• Other, n = 4
Allocation
Enrolment
Available for analysis (n = 112)
Excluded from the analysis (n = 20)
• Withdrew, n = 16
• Died prior to visit, n = 2
• Missed 6-week assessment, n = 2
• Withdrew, n = 10
• Died prior to visit, n = 5
• Missed 6-week assessment, n = 5
Available for analysis (n = 101)
Excluded from the analysis (n = 20)
Analysis week 6
Attended week 52 visit (n = 78)
Included in primary safety analysis 
(n = 121)
Excluded from the analysis (n = 36)
• Withdrew, n = 20
• Died prior to visit, n = 12
• Lost to follow-up, n = 4
• Withdrew, n = 13
• Died prior to visit, n = 14
• Lost to follow-up, n = 1
Attended week 52 visit (n = 78)
Included in primary safety analysis 
(n = 113)
Excluded from the analysis (n = 28)
Analysis week 52
FIGURE 3 Consolidated Standards of Reporting Trials flow chart. Those patients excluded from analysis at week 6
because they missed the week 6 assessment are included in the denominator at week 52 as they have the
possibility of attending a visit after week 6 and therefore are not considered lost to follow-up at week 6. Patients
who did not attend their week 52 visit are designated as lost to follow-up at week 52. Reproduced from Williams
et al.24 under the terms of the Creative Commons Attribution 4.0 licence (CC-BY) (https://creativecommons.org/
licenses/by/4.0).
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had mild disease (three to nine blisters). The two groups were also balanced for Karnofsky score of
functional impairment and ethnicity (Table 2).
Withdrawals
A total of 92 patients (36.8%) withdrew from the trial with a similar rate between the two arms (Tables 3
and 4). The most common reasons were withdrawal of consent and patient died. The withdrawal rate
remained similar throughout the 52-week follow-up period (Table 5 and Figure 4).
Adherence to interventions for primary effectiveness at
6 weeks
Of the participants who had data available for the week 6 primary effectiveness analysis (mITT population),
18.8% in the doxycycline group missed > 3 days of treatment during the first 6 weeks, compared with
5.0% in the prednisolone group (Table 6). Nausea was cited as the most frequent reason for reduced
adherence to doxycycline in the first 6 weeks (mentioned in 10/21 cases).
Primary outcomes
Primary effectiveness outcome
The primary effectiveness outcome was a non-inferiority comparison of the proportions of patients
achieving treatment success at 6 weeks, defined as three or fewer significant blisters. It was anticipated
that doxycycline would be less effective than prednisolone but that this would be accompanied by an
improvement in the safety profile. As is best practice for non-inferiority comparisons, both mITT and PP
analyses were performed.
Modified intention-to-treat analysis
The mITT population included all participants regardless of any changes to treatment, provided that they
had survived to week 6 and had received a blister count. This analysis reflects the comparison of the two
strategies of starting on doxycycline or starting on prednisolone. In total, 91.1% of patients who were
randomised to the prednisolone group were considered to be a treatment success at 6 weeks compared
TABLE 1 Numbers of participants randomised to each arm and reasons for ineligibility
Patient status Doxycycline Prednisolone Total
Number randomised 140 138 278
Number withdrawn because of ineligibility 8 17 25
Reasons for ineligibility
Both direct and indirect immunofluorescence tests were negative 4 15 19
Investigator felt on reflection that patient did not have sufficient
blisters to meet the inclusion criteria and therefore should be
withdrawn from the trial
0 1 1
Uncertainty initially about diagnosis, negative indirect
immunofluorescence, need for treatment
1 0 1
Patient ineligible for other reasons 3 1 4
Number to be analysed 132 121 253
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with 74.1% of patients who were randomised to the doxycycline group (Table 7). Although this is an
18.6% adjusted difference in effectiveness in favour of prednisolone (90% CI 11.1% to 26.1%), the upper
CI falls well within the prespecified bounds of non-inferiority (37%) and doxycycline can therefore be
considered non-inferior.
There was no evidence of an interaction between disease severity and treatment effect in either the mITT
or the PP population.
TABLE 2 Baseline characteristics
Characteristic Doxycycline, n (%) Prednisolone, n (%) Total, N (%)
Female 63 (47.7) 57 (47.1) 120 (47.4)
Male 69 (52.3) 64 (52.9) 133 (52.6)
Age (years)a 78.1 (9.5) 77.2 (10.0) 77.7 (9.7)
< 65 8 (6.1) 14 (11.6) 22 (8.7)
65 to < 75 38 (28.8) 33 (27.3) 71 (28.1)
75 to < 85 51 (38.6) 45 (37.2) 96 (37.9)
≥ 85 35 (26.5) 29 (24.0) 64 (25.3)
Karnofsky scorea 69.0 (18.3) 70.5 (17.6) 69.7 (18.0)
< 40 3 (2.3) 1 (0.8) 4 (1.6)
40 to < 55 32 (24.2) 26 (21.5) 58 (22.9)
55 to < 70 21 (15.9) 24 (19.8) 45 (17.8)
70 to < 85 45 (34.1) 38 (31.4) 83 (32.8)
≥ 85 31 (23.5) 32 (26.4) 63 (24.9)
Unable to care for self 16 (12.1) 11 (9.1) 27 (10.7)
Unable to work 55 (41.7) 51 (42.1) 106 (41.9)
Ableb 61 (46.2) 59 (48.8) 120 (47.4)
Ethnicity
White 112 (84.8) 100 (82.6) 212 (83.8)
Black – African 1 (0.8) 1 (0.8) 2 (0.8)
Black – other 0 1 (0.8) 1 (0.4)
Asian – Indian 2 (1.5) 1 (0.8) 3 (1.2)
Asian – Chinese 1 (0.8) 0 1 (0.4)
Asian – other 2 (1.5) 1 (0.8) 3 (1.2)
Other 0 1 (0.8) 1 (0.4)
Not known/given 14 (10.6) 16 (13.2) 30 (11.9)
Severity of BP
Mild (3–9 blisters) 42 (31.8) 38 (31.4) 80 (31.6)
Moderate (10–30 blisters) 53 (40.2) 46 (38.0) 99 (39.1)
Severe (> 30 blisters) 37 (28.0) 37 (30.6) 74 (29.2)
Total n 132 121 253
a Mean (standard deviation).
b Able to carry out normal activity and to work; no special care needed.
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TABLE 4 Numbers of participants withdrawn from the trial by each visit
Week Patient status
Doxycycline
(n= 132), n (%)
Prednisolone
(n= 121), n (%)
Total (N= 253),
N (%)
3 Seen 120 (90.9) 110 (90.9) 230 (90.9)
Died before visit 1 (0.8) 4 (3.3) 5 (2.0)
Withdrew before visit 9 (6.8) 5 (4.1) 14 (5.5)
Visit not conducted/status not known 2 (1.5) 2 (1.7) 4 (1.6)
Total expected 132 121 253
6 Seen 112 (91.8) 101 (90.2) 213 (91.0)
Died before visit, but after last scheduled visit 1 (0.8) 1 (0.9) 2 (0.9)
Withdrew before visit, but after last
scheduled visit
7 (5.7) 5 (4.5) 12 (5.1)
Visit not conducted/status not known 2 (1.6) 5 (4.5) 7 (3.0)
Total expected 122 112 234
13 Seen 99 (86.8) 94 (88.7) 193 (87.7)
Died before visit, but after last scheduled visit 5 (4.4) 5 (4.7) 10 (4.5)
Withdrew before visit, but after last
scheduled visit
3 (2.6) 6 (5.7) 9 (4.1)
Visit not conducted/status not known 7 (6.1) 1 (0.9) 8 (3.6)
Total expected 114 106 220
26 Seen 88 (83.0) 81 (85.3) 169 (84.1)
Died before visit, but after last scheduled visit 2 (1.9) 6 (6.3) 8 (4.0)
Withdrew before visit, but after last
scheduled visit
9 (8.5) 4 (4.2) 13 (6.5)
Visit not conducted/status not known 7 (6.6) 4 (4.2) 11 (5.5)
Total expected 106 95 201
continued
TABLE 3 Numbers of participants withdrawn from the trial and the primary reasons
Primary reason for withdrawal Doxycycline (n= 132), n Prednisolone (n= 121), n Total, N
Death 14 19 33a
Adverse event 2 1 3
Lost to follow-up 5 4 9
Treatment failure 4 1 5
Withdrew consent 23 16 39
Unable to tolerate trial medications 1 0 1
Other 1 1 2
Total 50 42 92
a In total, 34 deaths occurred in the trial but one participant withdrew consent before they subsequently died and hence
the total withdrawn because of death is 33 here.
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Per-protocol analysis
Patients were excluded from the PP analysis for deviations from the protocol that could significantly affect
the outcome. Patients may appear more than once under the various reasons for exclusion if they met
more than one of the criteria. The results of the PP analysis were very similar to the results of the ITT
analysis, with 92.3% of patients in the prednisolone group achieving success compared with 74.4% in the
doxycycline group, an adjusted difference of 18.7% (90% CI 9.8% to 27.6%) (Table 8), which falls well
within the 37% upper bound for the 90% CI.
Both the mITT and PP analyses are represented graphically in Figure 5.
TABLE 5 Cumulative number of participants withdrawn from the trial
Week Patient status
Doxycycline
(n= 132), n (%)
Prednisolone
(n= 121), n (%)
Total (N= 253),
N (%)
3 Died before visit 1 (0.8) 4 (3.3) 5 (2.0)
Withdrew before visit 9 (6.8) 5 (4.1) 14 (5.5)
6 Died before visit 2 (1.5) 5 (4.1) 7 (2.8)
Withdrew before visit 16 (12.1) 10 (8.3) 26 (10.3)
13 Died before visit 7 (5.3) 10 (8.3) 17 (6.7)
Withdrew before visit 19 (14.4) 16 (13.2) 35 (13.8)
26 Died before visit 9 (6.8) 16 (13.2) 25 (9.9)
Withdrew before visit 28 (21.2) 20 (16.5) 48 (19.0)
39 Died before visit 12 (9.1) 18 (14.9) 30 (11.9)
Withdrew before visit 33 (25.0) 23 (19.0) 56 (22.1)
52 Died before visit 14 (10.6) 19 (15.7) 33 (13.0)
Withdrew before visit 36 (27.3) 23 (19.0) 59 (23.3)
TABLE 4 Numbers of participants withdrawn from the trial by each visit (continued )
Week Patient status
Doxycycline
(n= 132), n (%)
Prednisolone
(n= 121), n (%)
Total (N= 253),
N (%)
39 Seen 81 (85.3) 79 (92.9) 160 (88.9)
Died before visit, but after last scheduled visit 3 (3.2) 2 (2.4) 5 (2.8)
Withdrew before visit, but after last
scheduled visit
5 (5.3) 3 (3.5) 8 (4.4)
Visit not conducted/status not known 6 (6.3) 1 (1.2) 7 (4.4)
Total expected 95 85 180
52 Seen 78 (89.7) 78 (97.5) 156 (93.4)
Died before visit, but after last scheduled visit 2 (2.3) 1 (1.3) 3 (1.8)
Withdrew before visit, but after last
scheduled visit
3 (3.4) 0 3 (1.8)
Visit not conducted/status not known 4 (4.6) 1 (1.3) 5 (3.0)
Total expected 87 80 167
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TABLE 7 Proportions of participants who achieved treatment success at 6 weeks: mITT analysis
Outcome
Number (%) of patients
Doxycycline Prednisolone
Success 83 (74.1) 92 (91.1)
Failure 29 (25.9) 9 (8.9)
Total 112 101
Difference in proportions (prednisolone – doxycycline) Adjusted:a 18.6% (90% CI 11.1% to 26.1%)
Unadjusted: 17.0% (90% CI 8.7% to 25.2%)
a Estimates are from a regression model adjusted for baseline severity of BP and Karnofsky score; however, age was
omitted from the model because the model failed to converge when age was added as an adjustment factor.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%. This analysis includes all patients who had a blister count at week 6, and excludes those
participants without a blister count at week 6, who were lost to follow-up or who died before week 6. Treatment
success = three or fewer significant blisters at week 6; treatment failure = four or more significant blisters at week 6.
TABLE 6 Adherence prior to week 6
Missed > 3 consecutive days
of treatment before week 6 Doxycycline, n (%) Prednisolone, n (%) Total, N (%)
Yes 21 (18.8) 5 (5.0) 26 (12.2)
No 91 (81.3) 96 (95.0) 187 (87.8)
Total 112 101 213
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FIGURE 4 Kaplan–Meier survival plot showing time to withdrawal (including death).
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Subgroup analyses
Two subgroup analyses were performed to test for treatment interactions. There were no significant
interactions in either the mITT or the PP populations between effectiveness at 6 weeks and baseline
disease severity (mild, moderate and severe) (Tables 9 and 10 respectively) or between effectiveness at
6 weeks and the blinding status of the investigator who carried out the week 6 blister count (Tables 11
and 12, respectively).
TABLE 8 Proportions of participants who achieved treatment success at 6 weeks: PP analysis
Outcome
Number (%) of patients
Doxycycline Prednisolone, n (%)
Success 58 (74.4) 84 (92.3)
Failure 20 (25.6) 7 (7.7)
Total 78 91
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 18.7 (9.8 to 27.6)
Unadjusted: 17.9 (8.6 to 27.3)
a Estimates are from a regression model adjusted for baseline severity of BP and Karnofsky score; however, age was
omitted from the model because the model failed to converge when age was added as an adjustment factor.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%. This analysis includes all patients who had a blister count at week 6, and excludes those
participants without a blister count at week 6, who were lost to follow-up or who died before week 6. Treatment
success = 0–3 significant blisters at week 6; treatment failure=≥ 4 significant blisters at week 6. (See Appendix 3, Table 58
for reasons for exclusion.)
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TABLE 10 Subgroup analysis of baseline disease severity and treatment effect: PP analysis
Outcome Subgroupa
Number (%) of patients Difference in proportions
achieving treatment success
(prednisolone – doxycycline)b
(90% CI) (%)
Interaction test
p-value
Doxycycline
(N= 78)
Prednisolone
(N= 91)
Difference in
proportions
(prednisolone –
doxycycline)b
Mild baseline
severity
22 (28.2) 26 (28.6) 23.4 (6.6 to 40.2) –
Moderate baseline
severity
34 (43.6) 40 (44.0) 24.8 (9.8 to 43.0) 0.672
Severe baseline
severity
22 (28.2) 25 (27.5) 7.3 (–13.1 to 27.7) 0.477
a Baseline severity: mild < 10 blisters; moderate 10–30 blisters; severe ≥ 30 blisters.
b Estimates are from a regression model adjusted for age and baseline severity; however, not adjusted for Karnofsky score
as model would not converge.
TABLE 11 Subgroup analysis of blinding status and treatment effect: mITT analysis
Outcome Subgroup
Number (%) of patients Difference in proportions
achieving treatment success
(prednisolone – doxycycline)a
(90% CI) (%)
Interaction test
p-value
Doxycycline
(N= 112)
Prednisolone
(N= 101)
Difference in
proportions
(prednisolone –
doxycycline)a
Medication was
not known
70 (62.5) 64 (63.4) 20.6 (9.8 to 31.4) 0.333
Medication
was known
42 (37.5) 37 (36.6) 21.9 (10.2 to 33.5) –
a Estimates are from a regression model not adjusted for age, Karnofsky score or baseline severity as model would
not converge.
TABLE 12 Subgroup analysis of blinding status and treatment effect: PP analysis
Outcome Subgroup
Number (%) of patients Difference in proportions
achieving treatment success
(prednisolone – doxycycline)a
(90% CI) (%)
Interaction test
p-value
Doxycycline
(N= 78)
Prednisolone
(N= 91)
Difference in
proportions
(prednisolone –
doxycycline)a
Medication was
not known
53 (68.0) 59 (64.8) 21.5 (10.0 to 33.0) 0.356
Medication
was known
25 (32.1) 32 (35.2) 10.6 (5.0 to 26.3) –
a Estimates are from a regression model not adjusted for age, Karnofsky score or baseline severity as model would
not converge.
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Primary safety outcome
The primary safety outcome was the proportion of patients who, during the 52 weeks following
randomisation, experienced at least one adverse event that was judged to be either grade 3 (severe),
grade 4 (life-threatening) or grade 5 (death) and possibly, probably or definitely related to study treatment.
The mITT population for this primary safety outcome included all those with data from at least one
scheduled visit, regardless of any changes to treatment. An adjusted regression model in which preceding
visits were set to zero was used to impute missing data to determine the sensitivity of the observed results
to the missing data.
The risk of experiencing a treatment-related severe, life-threatening or fatal adverse event for patients started
on doxycycline was 18.2%; this compared with 36.3% for those starting on prednisolone (Table 13). This
represents a difference of 19.0% (95% CI 7.9% to 30.1%) after adjusting for baseline severity of BP. Similar
results were obtained from a regression model in which missing data had been imputed: 22.5% of patients
in the doxycycline group experienced a treatment-related severe, life-threatening or fatal adverse event
compared with 40.0% in the prednisolone group, a difference of 18.4% (95% CI 6.0% to 30.8%) after
adjusting for baseline severity of BP (Table 14).
A higher number of participants in the prednisolone group than in the doxycycline group had a maximum
grade of adverse event of grade 3 (severe) and grade 5 (death) (Table 15). The pattern was the same for
the total number of adverse events of each grade (Table 16).
TABLE 14 Proportions of participants experiencing at least one adverse event of grade 3 or higher that was
possibly, probably or definitely related to study treatment (with imputed data): mITT analysis
Doxycycline Prednisolone
Proportion of patients with an adverse event of grade 3 or above (%)a 22.5 40.0
Difference in proportions (prednisolone – doxycycline) (95% CI) (%) Adjusted:b 18.4 (6.0 to 30.8); p= 0.004
Unadjusted: 17.5 (4.8 to 30.1); p= 0.007
a Estimates from unadjusted regression model on imputed data set.
b Estimates are from a regression model adjusted for baseline severity of BP; however, Karnofsky score and age were
omitted from the model because the model failed to converge when age and Karnofsky score were added as
adjustment factors.
TABLE 13 Proportions of participants experiencing at least one adverse event of grade 3 or higher that was
possibly, probably or definitely related to study treatment (raw data set): mITT analysis
Doxycycline Prednisolone
Proportion of patients with an adverse event of grade 3 or above (%)a 18.2 36.3
Difference in proportions (prednisolone – doxycycline) (95% CI) (%) Adjusted:b 19.0 (7.9 to 30.1); p= 0.001
Unadjusted: 18.1 (6.9 to 29.3); p= 0.002
a Estimates from unadjusted regression model.
b Estimates are from a regression model adjusted for baseline severity of BP; however, Karnofsky score and age were
omitted from the model because the model failed to converge when age and Karnofsky score were added as
adjustment factors.
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Secondary outcomes
Secondary effectiveness outcome: weeks 6, 13 and 52
For secondary effectiveness outcomes, the definition of treatment success was different from that used for
the primary effectiveness outcome. A participant was required to have three or fewer significant blisters
present on examination to be considered a treatment success but, unlike the primary effectiveness analysis,
patients who had had their treatment modified because of a poor response (change of medication or
dose of randomised medication increased) prior to the visit did not qualify as a success in the secondary
analyses. This difference is because the primary effectiveness outcome assessed the strategy of starting on
doxycycline or starting on prednisolone, whereas the secondary outcomes assessed the effectiveness of the
treatments used as longer-term monotherapy. All secondary effectiveness outcomes are non-inferiority analyses.
The proportion of patients classed as a treatment success at 6 weeks in the mITT analysis, according to the
definition of success described above, was 85.4% in the prednisolone group and 53.6% in the doxycycline
group (Table 17). This represents a difference of 31.8% (90% CI 22.5% to 41.2%) in favour of prednisolone
after adjusting for baseline severity of BP and age. The PP analysis showed similar results, with a difference of
34.4% (90% CI 23.7% to 45.1%) in favour of prednisolone after adjusting for baseline severity of BP and
TABLE 16 Total number of grade 3, 4 and 5 related adverse events: mITT analysis
Adverse event
Number (%) of adverse events (mean per participant)
Doxycycline (N= 121) Prednisolone (N= 113)
Grade 3 (severe) 33 (0.3)a 59 (0.5)
Grade 4 (life-threatening) 9 (0.1) 9 (0.1)
Grade 5 (death) 3 (< 0.1) 11 (0.1)
Grades 3–5 45 (0.4) 79 (0.7)
a Includes one suspected unexpected serious adverse reaction (hypoglycaemia).
Note
This table includes all patients who have at least one record of an adverse event assessment from the scheduled visit
adverse event assessments or a recorded serious adverse event or death.
TABLE 15 The maximum grade of adverse event that each participant experienced during the trial that was
considered possibly, probably or definitely related to the study drug: mITT analysis
Adverse event
Number (%) of patients
Doxycycline
(N= 121)
Prednisolone
(N= 113)
No adverse events or maximum grade of 1 (mild) or 2 (moderate) 99 (81.8) 72 (63.7)
Maximum grade of 3 (severe) 14 (11.6) 25 (22.1)
Maximum grade of 4 (life-threatening) 5 (4.1) 5 (4.4)
Maximum grade of 5 (death) 3 (2.5) 11 (9.7)
Maximum grade of 3, 4 or 5 22 (18.2) 41 (36.3)
Note
Participants counted only once in this table as per their highest grade of adverse event.
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age (Table 18). The upper CIs for both analyses fall just outside the prespecified upper bound of 37%.
Subgroup analyses of the effectiveness outcome data at week 6 using the secondary outcome definition
failed to show any evidence of interaction between disease severity and treatment effect (Tables 19 and 20)
in either the mITT or the PP population. There was no interaction between blinding status and treatment
effect at 6 weeks using the secondary outcome definition in the mITT analysis (Table 21) but there was some
evidence of an interaction effect when a PP analysis was done (Table 22).
TABLE 18 Proportions of participants who achieved treatment success at 6 weeks: PP analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Success 41 (52.6) 81 (87.1)
Failure
High blister count 20 (25.6) 7 (7.5)
Changed treatment 17 (21.8) 3 (3.2)
Died before week 6 0 2 (2.2)
Total 78 93
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 34.4 (23.7 to 45.1)
Unadjusted: 34.5 (23.6 to 45.4)
a Estimates are from a regression model adjusted for baseline severity of BP and age; however, Karnofsky score was
omitted from the model because the model failed to converge when Karnofsky score was added as an adjustment
factor. (See Appendix 3, Table 59 for reasons for exclusion.)
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment the upper bound of the 90% CI
should fall below 37%. Only patients with available data on blister count at week 6 or who had died before week 6 and
the cause was considered at least possibly related to treatment were included in this analysis.
TABLE 17 Proportions of participants who achieved treatment success at 6 weeks: mITT analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Successa 60 (53.6) 88 (85.4)
Failure
High blister countb 29 (25.9) 9 (8.7)
Changed treatment 23 (20.5) 4 (3.9)
Died before week 6 0 2 (1.9)
Total 112 103
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:c 31.8 (22.5 to 41.2)
Unadjusted: 31.9 (22.2 to 41.5)
a Patients who had had their treatment modified because of a poor response prior to the visit did not qualify as a success
in this secondary analyses.
b More than three blisters.
c Estimates are from a regression model adjusted for baseline severity of BP and age; however, Karnofsky score was omitted
from the model because the model failed to converge when Karnofsky score was added as an adjustment factor.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment the upper bound of the 90% CI
should fall below 37%. Only patients with available data on blister count at week 6 or who had died before week 6 and
the cause was considered at least possibly related to treatment were included in this analysis.
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At 13 weeks, in the mITT analysis, 75.3% of patients in the prednisolone group were considered a
treatment success compared with 58.6% in the doxycycline group, a difference of 17.5% (90% CI 6.8%
to 28.2%) in favour of prednisolone after adjusting for baseline severity of BP and age (Table 23). Again,
similar results were noted for the PP analysis (a difference of 17.3% in favour of prednisolone, 90% CI
4.9% to 29.7%) (Table 24).
TABLE 20 Subgroup analysis of baseline disease severity and the proportion of participants who achieved
treatment success at 6 weeks: PP analysis
Outcome Subgroup
Number (%) of patients Difference in proportions
achieving treatment success
(prednisolone – doxycycline)
(90% CI) (%)
Interaction test
p-value
Doxycycline
(N= 78)
Prednisolone
(N= 93)
Difference in
proportions
(prednisolone –
doxycycline)a
Mild baseline
blister severity
(< 10)
22 (28.2) 27 (29.0) 33.4 (14.3 to 52.5) –
Moderate baseline
blister severity
(10–30)
34 (43.6) 40 (43.0) 34.2 (18.2 to 50.2) 0.956
Severe baseline
blister severity
(> 30)
22 (28.2) 26 (28.0) 36.1 (14.1 to 58.1) 0.878
a Estimates are from a regression model adjusted for age and baseline severity; however, not adjusted for Karnofsky score
as model would not converge.
TABLE 19 Subgroup analysis of baseline disease severity and the proportion of participants who achieved
treatment success at 6 weeks: mITT analysis
Outcome Subgroup
Number (%) of patients Difference in proportions
achieving treatment success
(prednisolone – doxycycline)
(90% CI) (%)
Interaction test
p-value
Doxycycline
(N= 112)
Prednisolone
(N= 103)
Difference in
proportions
(prednisolone –
doxycycline)a
Mild baseline
blister severity
(< 10)
37 (33.0) 32 (31.1) 28.5 (12.9 to 44.2) –
Moderate baseline
blister severity
(10–30)
46 (41.1) 42 (40.8) 31.7 (17.5 to 45.8) 0.806
Severe baseline
blister severity
(> 30)
29 (25.9) 29 (28.2) 37.9 (18.0 to 58.8) 0.543
a Estimates are from a regression model adjusted for age and baseline severity; however, not adjusted for Karnofsky score
as model would not converge. Patients who died before they had a week 6 blister count were counted as ‘not
a success’.
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TABLE 22 Subgroup analysis of baseline blinding status and the proportion of participants who achieved
treatment success at 6 weeks: PP analysis
Outcome Subgroup
Number (%) of patients Difference in proportions
achieving treatment success
(prednisolone – doxycycline)
(90% CI) (%)
Interaction test
p-value
Doxycycline
(N= 78)
Prednisolone
(N= 91)
Difference in
proportions
(prednisolone –
doxycycline)a
Medication was
not known
53 (67.9) 59 (64.8) 25.0 (12.2 to 37.8) –
Medication
was known
25 (32.1) 32 (35.2) 57.7 (40.3 to 75.1) 0.013
a Estimates are from a regression model adjusted for age and baseline severity; however, not adjusted for Karnofsky score
as model would not converge.
TABLE 21 Subgroup analysis of baseline blinding status and the proportion of participants who achieved
treatment success at 6 weeks: mITT analysis
Outcome Subgroup
Number (%) of patients Difference in proportions
achieving treatment success
(prednisolone – doxycycline)
(90% CI) (%)
Interaction test
p-value
Doxycycline
(N= 112)
Prednisolone
(N= 101)
Difference in
proportions
(prednisolone –
doxycycline)a
Medication was
not known
70 (62.5) 64 (63.4) 25.1 (13.7 to 36.5) –
Medication
was known
42 (37.5) 37 (36.6) 46.2 (31.6 to 60.9) 0.059
a Estimates are from a regression model adjusted for age and baseline severity; however, not adjusted for Karnofsky score
as model would not converge.
TABLE 23 Proportions of participants who achieved treatment success at 13 weeks: mITT analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Success 58 (58.6) 76 (75.2)
Failure
High blister count 12 (12.1) 6 (5.9)
Changed treatment 29 (29.3) 12 (11.9)
Died before week 13 0 7 (6.9)
Total 99 101
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 17.5 (6.8 to 28.2)
Unadjusted: 16.7 (5.9 to 27.4)
a Estimates are from a regression model adjusted for baseline severity of BP and age; however, Karnofsky score was omitted
from the model because the model failed to converge when Karnofsky score was added as an adjustment factor.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment the upper bound of the 90% CI
should fall below 37%. Only patients with available data on blister count at week 13 or who died before week 13 and the
cause was considered at least possibly related to treatment were included in this analysis.
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The longer-term assessment of effectiveness (the proportion classed as a success at 52 weeks) shows that,
in the adjusted mITT analysis, 41.0% of patients started on doxycycline compared with 51.1% of those
started on prednisolone achieved treatment success, a difference of 10.0% (90% CI –2.3% to 22.2%) in
favour of prednisolone (Table 25). Similar results were seen for the PP analysis, with a difference of 7.1%
(90% CI –7.1% to 21.3%) in favour of prednisolone (Table 26).
TABLE 25 Proportions of participants who achieved treatment success at 52 weeks: mITT analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Success 34 (41.0) 45 (51.1)
Failure
High blister count 3 (3.6) 3 (3.4)
Changed treatment 43 (51.8) 29 (33.0)
Died before week 52 3 (3.6) 11 (12.5)
Total 83 88
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 10.0 (–2.3 to 22.2)
Unadjusted: 10.2 (–2.3 to 22.6)
a Estimates are from a regression model adjusted for baseline severity of BP and age; however, Karnofsky score was omitted
from the model because the model failed to converge when Karnofsky score was added as an adjustment factor.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment the upper bound of the 90% CI
should fall below 37%. Only patients with available data on blister count at week 52 or who died before week 52 and the
cause was considered at least possibly related to treatment were included in this analysis.
TABLE 24 Proportions of participants who achieved treatment success at 13 weeks: PP analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Success 38 (60.3) 71 (78.0)
Failure
High blister count 5 (7.9) 5 (5.5)
Changed treatment 20 (31.8) 9 (9.9)
Died before week 13 0 6 (6.6)
Total 63 91
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 17.3 (4.9 to 29.7)
Unadjusted: 17.7 (5.3 to 30.1)
a Estimates are from a regression model adjusted for baseline severity of BP and age; however, Karnofsky score was
omitted from the model because the model failed to converge when Karnofsky score was added as an adjustment
factor. (See Appendix 3, Table 60 for reasons for exclusion.)
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%. Only patients with available data on blister counts at week 13, or have died before week 13 and
the cause was considered at least possibly related to treatment were included in this analysis.
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Secondary outcome: relapse rates
Another measure of the long-term effectiveness of the two treatments was the proportion of participants
who had a further episode of BP during their participation in the study after previously being classed as a
treatment success. A participant was classed as having a relapse if he or she had a further episode of BP,
defined as more than three significant blisters, or a change or escalation of treatment because of
worsening of disease during participation in the study after previously being classed as a treatment success
(either three or fewer significant blisters present on prior examination or previously classed as a treatment
success on the treatment log). After adjusting for baseline severity, age and Karnofsky score, a similar
number of relapses occurred in the doxycycline group and the prednisolone group in the mITT population
(2.1% more in the prednisolone group, 90% CI –8.3% to 12.5%) (Table 27). A larger difference was
noted in the PP analysis (11.0% more relapses in the prednisolone group, 90% CI –1.2% to 23.2%)
(Table 28).
TABLE 26 Proportions of participants who achieved treatment success at 52 weeks: PP analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Success 24 (45.3) 41 (53.3)
Failure
High blister count 2 (3.8) 3 (3.9)
Changed treatment 25 (47.2) 23 (29.9)
Died before week 52 2 (3.8) 10 (13.0)
Total 53 77
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 7.1 (–7.1 to 21.3)
Unadjusted: 8.0 (–6.7 to 22.6)
a Estimates are from a regression model adjusted for baseline severity of BP and age; however, Karnofsky score was
omitted from the model because the model failed to converge when Karnofsky score was added as an adjustment
factor. (See Appendix 3, Table 61 for reasons for exclusion.)
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment the upper bound of the 90% CI
should fall below 37%. Only patients with available data on blister count at week 52 or who died before week 52 and the
cause was considered at least possibly related to treatment were included in this analysis.
TABLE 27 Proportions of participants who had a further episode of BP after previously being classified as a
treatment success: mITT analysis
Outcome
Number (%) of patients
Doxycycline Prednisolone
Relapse 37 (32.5) 39 (35.8)
No relapse 77 (67.5) 70 (64.2)
Total 114 109
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 2.1 (–8.3 to 12.5)
Unadjusted: 3.3 (–7.1 to 13.8)
a Estimates are from a regression model adjusted for baseline severity of BP, age and Karnofsky score.
Note
All patients who had at least one physical examination in the study and who had been classed as a treatment success at
some point in the trial were included in this analysis.
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Secondary outcome: combined outcome of effectiveness at 6 weeks and
safety over 52 weeks
To provide an overall measure of success, a combined analysis of effectiveness and safety is presented in a
superiority analysis. In the prednisolone group, 74.8% of patients were classed as a treatment success at
6 weeks and were alive at 52 weeks whereas in the doxycycline group 50.0% of patients were classed as
a treatment success at 6 weeks and were alive at 52 weeks (Table 29). This represents a difference of
25.0% (95% CI 13.1% to 37.0%) in favour of prednisolone after adjusting for baseline severity and age.
Secondary safety outcome: all adverse events
This secondary outcome includes all adverse events that are possibly, probably or definitely related to the
trial medication, regardless of severity. All analyses were carried out on a superiority basis. The maximum
TABLE 29 Proportions of patients who were classed as a treatment success at 6 weeks and were alive at 52 weeks
Treatment success
Number (%) of patients
Doxycycline Prednisolone
Success 56 (50.0) 77 (74.8)
Failure
Success at week 6 but not alive at week 52 4 (3.6) 11 (10.7)
Not successful at week 6 because of high blister count 29 (25.9) 9 (8.7)
Not successful at week 6 because of treatment change before week 6 23 (20.5) 4 (3.9)
Not successful at week 6 because of death before week 6 0 2 (1.9)
Total 112 103
Difference in proportions (prednisolone – doxycycline) (95% CI) (%) Adjusted:a 25.0 (13.1 to 37.0); p< 0.001
Unadjusted: 24.8 (14.3 to 35.2); p< 0.001
a Estimates are from a regression model adjusted for baseline severity of BP and age; however, Karnofsky score was omitted
from the model because the model failed to converge when Karnofsky score was added as an adjustment factor.
Note
This analysis includes all patients with a blister count at week 6 or who died before week 6 and the death was considered
at least possibly related to the treatment.
TABLE 28 Proportions of participants who had a further episode of BP after previously being classified as a
treatment success: PP analysis
Outcome
Number (%) of patients
Doxycycline Prednisolone
Relapse 20 (27.0) 34 (38.6)
No relapse 54 (73.0) 54 (61.4)
Total 74 88
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 11.0 (–1.2 to 23.2)
Unadjusted: 11.6 (–0.4 to 23.7)
a Estimates are from a regression model adjusted for baseline severity of BP, age and Karnofsky score. (See Appendix 3,
Table 62 for reasons for exclusion.)
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment the upper bound of the 90% CI
should fall below 37%. All patients who had at least one physical examination in the study and who had been classed as a
treatment success at some point in the trial were included in this analysis.
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grade of related adverse events experienced by participants during the trial is shown in Table 30. Patients
in the prednisolone group were significantly more likely to experience an adverse event that was related to
the study medication than those in the doxycycline group (95.7% vs. 86.2%, 95% CI 1.8% to 17.2%;
p = 0.016, unadjusted because of non-convergence in the model) (Table 31). The total numbers of related
adverse events by grade (raw data) are shown in Table 32.
Secondary outcome: quality of life
Quality of life was assessed using the generic EQ-5D and the skin-specific DLQI. For a specific visit, the
EQ-5D tabulations and analyses were conducted on all patients in the ITT population who had all five
scores for the five questions for that visit (mobility, self-care, usual activity, pain/discomfort and
anxiety/depression). Only patients who had at least one visit (not including baseline) for which data were
available were included in the analysis. The EQ-5D score (social preference score) was obtained, with a
value assigned to each combination of scores from the individual five questions (see Chapter 4, Data sources).
For the DLQI, the tabulations and analyses were conducted for a specific visit on all patients in the ITT
population who had all 10 scores for the 10 questions for that visit. Only patients who had at least one
visit (not including baseline) for which data were available were included in the analysis. The DLQI score
was calculated as the sum of each of the scores for the 10 questions asked at each visit.
TABLE 30 The maximum grade of adverse event that each participant experienced during the trial that was
considered possibly, probably or definitely related to the study drug (any grade): raw data
Adverse event
Number (%) of patients
Doxycycline (N= 121)
Prednisolone
(N= 113)
No adverse events 23 (19.0) 13 (11.5)
Maximum grade of adverse event grade 1 (mild) 20 (16.5) 16 (14.2)
Maximum grade of adverse event grade 2 (moderate) 56 (46.3) 43 (38.1)
Maximum grade of adverse event grade 3 (severe) 14 (11.6) 25 (22.1)
Maximum grade of adverse event grade 4 (life-threatening) 5 (4.1) 5 (4.4)
Maximum grade of adverse event grade 5 (death) 3 (2.5) 11 (9.7)
Adverse event of any grade 98 (81.0) 100 (88.5)
Note
This table includes all patients with at least one record of an adverse event assessment from the scheduled visit adverse
event assessments or a recorded serious adverse event or death.
TABLE 31 Proportions of patients with any related adverse event during the trial: mITT analysis
Doxycycline Prednisolone
Proportion of patients with an adverse event (%)a 86.2 95.7
Difference in proportion of patients with an adverse event
(prednisolone – doxycycline) (95% CI) (%)
Unadjusted:b 9.5 (1.8 to 17.2); p= 0.016
a Estimates are from an unadjusted regression model on the imputed data set.
b Estimates are from a regression model not adjusted for baseline severity of BP, Karnofsky score and age because the
model failed to converge when they were added as adjustment factors.
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There was a median change in EQ-5D score from baseline to week 52 of +0.090 in the doxycycline group
and +0.071 in the prednisolone group (Table 33). When this was adjusted for baseline EQ-5D score,
baseline severity, age and Karnofsky score, the difference was not significant (0.045, 95% CI –0.015 to
0.106; p = 0.143) (Table 34). Patients in the two groups had a similar improvement in DLQI score, with a
median improvement from baseline to week 52 of 9 points in the doxycycline group and 10 points in
the prednisolone group (Table 35). When adjusted for baseline DLQI score, baseline severity, age and
Karnofsky score, there was a significant difference of –1.8 (95% CI –2.58 to –1.01) in favour of
doxycycline (Table 36).
Tertiary outcomes
The mITT analysis showed that there was a higher proportion of participants who were completely blister
free at 6 weeks (rather than three or fewer significant blisters) in the prednisolone group (73.3% vs.
TABLE 32 Total number of related adverse events by grade: raw data
Adverse event
Number of adverse events (mean per participant)
Doxycycline (n= 121) Prednisolone (n= 113)
Grade 1 (mild) 210 (1.7) 234 (2.1)
Grade 2 (moderate) 158 (1.3) 129 (1.1)
Grade 3 (severe) 33 (0.3) 59 (0.5)
Grade 4 (life-threatening) 9 (0.1) 9 (0.1)
Grade 5 (death) 3 (< 0.1) 11 (0.1)
Grades 1–5 413 (3.4) 442 (3.9)
Note
This table includes all patients who have at least one record of an adverse event assessment from the scheduled visit
adverse event assessments or a recorded serious adverse event or death.
TABLE 33 Difference in EQ-5D scores (raw data): mITT analysis
Time
point
Doxycycline (n= 110) Prednisolone (n= 101)
Median (IQR)
Median change
from baseline
Total patients
with data Median (IQR)
Median change
from baseline
Total patients
with data
Baseline 0.656
(0.273–0.796)
0 110 0.656
(0.273–0.760)
0 101
Week 6 0.620
(0.353–0.805)
–0.036 108 0.746
(0.587–1.000)
+0.090 96
Week 13 0.710
(0.450–1.000)
+0.054 96 0.779
(0.639–0.925)
+0.123 92
Week 26 0.746
(0.587–1.000)
+0.090 85 0.796
(0.638–0.850)
+0.140 80
Week 39 0.727
(0.587–1.000)
+0.071 79 0.710
(0.587–1.000)
+0.054 77
Week 52 0.746
(0.587–1.000)
+0.090 78 0.727
(0.587–1.000)
+0.071 74
IQR, interquartile range.
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45.9%) (Table 37). This is a difference of 28.6% in favour of prednisolone after adjusting for baseline
severity, age and Karnofsky score (90% CI 18.1 to 39.1%). Table 38 lists the number of patients in the
mITT population excluded from the PP analysis. The PP analysis showed very similar results (Table 39).
Tertiary effectiveness outcome: proportion of participants who achieved
treatment success at 3 weeks (non-inferiority)
As a measure of the speed of onset of action, the proportions of participants classed as a treatment
success (three or fewer significant blisters) were assessed after only 3 weeks of treatment. In the mITT
population, a higher proportion of those started on prednisolone were classed as a treatment success at
3 weeks than those started on doxycycline, with a difference of 23.4% (90% CI 14.4% to 32.5%) after
adjusting for baseline severity, age and Karnofsky score (Table 40), although this remains within the
prespecified bounds of non-inferiority. A similar difference was seen in the PP analysis (Table 41).
TABLE 34 Difference in EQ-5D scores: mITT analysis
Difference in EQ-5D scores (prednisolone – doxycycline) (95% CI) Adjusted:a 0.045 (–0.015 to 0.106); p= 0.143
Unadjusted:b 0.062 (–0.006 to 0.130); p= 0.076
a Visit was entered into the model as a random intercept nested within the patient. Estimates from a mixed-effects
regression model adjusted for baseline EQ-5D score, baseline severity of BP, age and Karnofsky score.
b Visit was entered into the model as a random intercept nested within the patient. Estimates from a mixed-effects
regression model unadjusted for baseline severity of BP, age and Karnofsky score but adjusted for baseline EQ-5D score.
TABLE 35 Difference in DLQI scores (raw data): mITT analysis
Time
point
Doxycycline (n= 108) Prednisolone (n= 101)
Median (IQR)
Median change
from baseline
Total patients
with data Median (IQR)
Median change
from baseline
Total patients
with data
Baseline 10 (6–15) 0 108 11 (6–14) 0 101
Week 6 5 (2–9) –5 106 1 (0–3) –10 96
Week 13 2 (1–6) –8 98 1 (0–4) –10 90
Week 26 2 (0–4) –8 86 1 (0–3) –10 80
Week 39 1 (0–4) –9 80 1 (1–3) –10 77
Week 52 1 (0–3) –9 79 1 (0–3) –10 75
IQR, interquartile range.
TABLE 36 Difference in DLQI scores: mITT analysis
Difference in DLQI scores (prednisolone – doxycycline) (95% CI) (%) Adjusted:a,b –1.80 (–2.58 to –1.01); p< 0.001
a Visit was entered into the model as a random intercept nested within the patient. Estimates from a mixed-effects
regression model adjusted for baseline DLQI score, baseline severity of BP, age and Karnofsky score.
b The model did not converge in the unadjusted analysis and so this has been omitted.
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TABLE 37 Proportions of participants who were completely blister free at week 6: mITT analysis
Outcome
Number (%) of patients)
Doxycycline Prednisolone
Blister free 51 (45.9) 74 (73.3)
Not blister free 60 (54.1) 27 (26.7)
Total 111 101
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 28.6 (18.1 to 39.1)
Unadjusted: 27.3 (16.7 to 38.0)
a Estimates are from a regression model adjusted for baseline severity of BP, age and Karnofsky score.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%. All patients who had data on whether or not they were blister free at week 6 were included in this
analysis. One patient who was included in the primary efficacy analysis but who did not have data available on whether or
not they were blister free at week 6 was excluded from the analysis.
TABLE 38 Number of patients in the mITT population excluded from the PP analysis
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment before week 6 1 0
Changed treatment or added a new treatment to the allocated
treatment before week 6
17 3
Used topical steroids between weeks 3 and 6 7 3
Missed more than 3 consecutive days of treatment before week 6 21 5
Total number of non-PP patients 34 10
Note
Some patients may appear in more than one row.
TABLE 39 Proportions of participants who were completely blister free at week 6: PP analysis
Outcome
Number (%) of patients
Doxycycline Prednisolone
Blister free 35 (45.5) 68 (74.7)
Not blister free 42 (54.5) 23 (25.3)
Total 77 91
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 30.2 (18.4 to 42.0)
Unadjusted: 29.3 (17.3 to 41.2)
a Estimates are from a regression model adjusted for baseline severity of BP, age and Karnofsky score.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%. All patients who had data on whether or not they were blister free at week 6 were included in this
analysis. One patient who was included in the primary efficacy analysis but who did not have data available on whether or
not they were blister free at week 6 was excluded from the analysis.
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Tertiary safety outcome: mortality over the 52-week follow-up period
(superiority)
An assessment of all deaths, regardless of any relatedness to the study medication, was performed. Those
who started on prednisolone were more likely to die during the year of follow-up than those started on
doxycycline (83.5% alive at 1 year compared with 89.4%, respectively) (Table 42). The hazard ratio for
reduction in death in favour of doxycycline, adjusted for baseline severity, age and Karnofsky score,
was 0.61 (95% CI 0.30 to 1.24; p = 0.173) (Table 43). Time to death is shown in the Kaplan–Meier plot
in Figure 6.
TABLE 40 Proportions of participants who achieved treatment success at 3 weeks: mITT analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Success 67 (56.3) 90 (81.1)
Failure
High blister count 42 (35.3) 17 (15.3)
Changed treatment 10 (8.4) 3 (2.7)
Died before week 3 0 1 (0.9)
Total 119 111
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 23.4 (14.4 to 32.5)
Unadjusted: 24.8 (15.1 to 34.4)
a Estimates are from a regression model adjusted for baseline severity of BP and Karnofsky score; however, age was
omitted from the model because the model failed to converge when age was added as an adjustment factor.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%. Only patients with available data on blister count at week 3 or who died before week 3 and the
cause was considered at least possibly related to treatment were included in this analysis.
TABLE 41 Proportions of participants who achieved treatment success at 3 weeks: PP analysis
Treatment outcome
Number (%) of patients
Doxycycline Prednisolone
Success 56 (57.1) 85 (81.7)
Failure
Severe baseline disease 33 (33.7) 16 (15.4)
Changed treatment 9 (9.2) 3 (2.9)
Died before week 3 0 0
Total 98 104
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 23.7 (13.3 to 34.0)
Unadjusted: 24.6 (14.3 to 34.9)
a Estimates are from a regression model adjusted for Karnofsky score; however, baseline severity of BP and age were
omitted from the model because the model failed to converge when they were added as adjustment factors.
(See Appendix 3, Table 63 for reasons for exclusion.)
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%.
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Tertiary effectiveness outcome: use of potent and superpotent topical
corticosteroids during the 52-week follow-up period (superiority)
Use of topical steroids (potent or superpotent) was permitted during the first 3 weeks of treatment for
symptomatic relief (no more than 30 g per week to localised lesions only) and also after 6 weeks, as might
occur in normal practice in the UK. Although use of topical steroids was discouraged from the end of
week 3 to the week 6 effectiveness assessment, some participants did use topical corticosteroids for local
relief of the affected area. Data on quantities of topical corticosteroids used were not collected accurately
over the 1-year study period and so Table 44 presents topical corticosteroid use during different study
periods. As anticipated, topical corticosteroid use for symptomatic relief was greater at all time points for
those initiated on doxycycline treatment.
TABLE 42 Mortality over the 52-week follow-up period: mITT analysis
Mortality outcome
Number (%) of patients
Doxycycline (N= 132) Prednisolone (N= 121)
Died during trial follow-up 14 (10.6) 20a (16.5)
Relateda 3 (2.3) 11 (9.1)
Unrelatedb 11 (8.3) 9 (7.4)
Alive at the end of follow-up (1 year) 118 (89.4) 101 (83.5)
a Includes a participant who withdrew consent and who subsequently died.
b Related refers to the death being considered at least possibly related to the trial treatment.
TABLE 43 All-cause mortality: mITT analysis
All-cause mortality (hazard ratio) (95% CI) Adjusted:a 0.61 (0.30 to 1.24); p= 0.173
Unadjusted: 0.59 (0.29 to 1.19); p= 0.139
a Estimate is from a Cox regression model adjusted for baseline severity of BP, age and Karnofsky score.
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FIGURE 6 Kaplan–Meier survival plot showing time to death.
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Additional post-hoc analysis
Post-hoc analysis: primary effectiveness outcome repeated at week 52
The primary effectiveness outcome at 6 weeks assessed the strategy of starting on doxycycline or
prednisolone by including all participants regardless of any treatment modification. It was decided at the
Trial Steering Committee meeting to conduct an additional post-hoc effectiveness analysis using the same
definition of the population included to assess the strategy of starting on doxycycline or prednisolone over
the whole 52-week period. There was no significant difference between the two groups when assessed
over the full 52 weeks in either the mITT analysis (Table 45) or the PP analysis (Table 46).
Post-hoc analysis: action (treatment changes) taken in response to relapse
In total, 76 patients were identified as having relapsed after previously being classified as a treatment
success, either because they had three or fewer significant blisters present or because they had ceased trial
medication because of treatment success (Table 47). For those started on prednisolone, if they experienced
a relapse, patients usually either received an increased dose of prednisolone (30/39, 76.9%) or
recommenced prednisolone if treatment had ceased completely (8/39, 20.5%). For those who started on
TABLE 44 Potent and superpotent topical corticosteroid use according to study period and treatment allocation
Time period
Doxycycline (N= 112), n (%) Prednisolone (N= 101), n (%)
Potent Superpotent
Patients
using topical
corticosteroids Potent Superpotent
Patients
using topical
corticosteroids
After randomisation
up to 3 weeks
6 (5.4) 1 (0.9) 7 (6.3) 3 (3.0) 1 (1.0) 4 (4.0)
After 3 weeks up to
6 weeks
12 (10.7) 11 (9.8) 23 (20.5) 6 (5.9) 0 6 (5.9)
After 6 weeks 5 (4.5) 7 (6.3) 12 (10.7) 2 (2.0) 0 2 (2.0)
At any time during
the trial
13 (11.6) 11 (9.8) 24 (21.4) 6 (5.9) 1 (1.0) 7 (6.9)
TABLE 45 Proportions of participants who achieved treatment success at 52 weeks: mITT analysis
Outcomea
Number (%) of patients
Doxycycline Prednisolone
Success 77 (96.3) 74 (96.1)
Failure 3 (3.8) 3 (3.9)
Total 80 77
Difference in proportions (prednisolone – doxycycline) (90% CI) (%)b –0.1 (–5.2 to 4.9)
a Three or fewer significant blisters at week 6 = treatment success; four or more significant blisters at week 6 or died
before week 6 = treatment failure.
b Estimates are from a regression model unadjusted for baseline severity of BP, age and Karnofsky score as adding any of
these covariates into the model led to non-convergence of the model.
Notes
This analysis includes all patients with a blister count at week 52 and excludes those who did not have a blister count at
week 6 and who were lost to follow-up or who died before week 52.
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%.
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doxycycline, the most common course of action on relapse after having previously achieved disease control
was to change to prednisolone (13/37, 35.1%) or increase the dose of prednisolone (16/37, 43.2%).
Post-hoc analysis: time to switching treatment
For those patients who switched treatments, the time between starting the study and switching treatment
was assessed in a post-hoc analysis. This included all of the patients in the mITT population who contributed
to the secondary efficacy analysis at week 6. The rate of switching from doxycycline was greatest during
the first 6 weeks; after 13 weeks there was very little switching (Figure 7). There was a lower rate of
switching for those starting on prednisolone and the rate was more constant over the whole 52 weeks.
TABLE 46 Proportions of participants who achieved treatment success at 52 weeks: PP analysis
Outcomea
Number (%) of patients
Doxycycline Prednisolone
Success 49 (96.1) 64 (95.5)
Failure 2 (3.9) 3 (4.5)
Total 51 67
Difference in proportions (prednisolone – doxycycline) (90% CI) (%)b –0.6 (–6.7 to 5.5)
a Three or fewer significant blisters at week 6= treatment success; four or more significant blisters at week 6 or died
before week 6 = treatment failure.
b Estimates are from a regression model unadjusted for baseline severity of BP, age and Karnofsky score as adding any of
these covariates into the model led to non-convergence of the model. (See Appendix 3, Table 64 for reasons
for exclusion.)
Note
This analysis includes all patients with a blister count at week 52 and excludes those who did not have a blister count at
week 6 and who were lost to follow-up or who died before week 52.
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%.
TABLE 47 Action taken in response to disease relapse
Action taken in response to disease relapse
Number (%) of patients
Doxycycline (n= 37) Prednisolone (n= 39)
Treatment changed to prednisolone 13 (35.1) 0
Treatment changed to doxycycline 0 0
Dose of prednisolone increased 16 (43.2) 30 (76.9)
Dose of doxycycline increased 3 (8.1) 0
Prednisolone restarted 3 (8.1) 8 (20.5)
Doxycycline restarted 2 (5.4) 0
Other treatment change 0 1 (2.6)
Note
This table refers to changes made at the point of relapse. In some instances, when a patient was allocated to a particular
treatment, the action may be to increase the dose, restart the allocated drug or start or restart the unallocated drug. This is
because the patient may have already changed treatment to an unallocated treatment prior to relapse, e.g. because of
treatment failure.
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Post-hoc analysis: sensitivity of the primary effectiveness outcome at
6 weeks to topical corticosteroid use
A slightly different definition of a PP violator was used from that defined in the statistical analysis plan so
that any use of a prohibited potent or superpotent topical corticosteroid between weeks 3 and 6 resulted
in exclusion from the PP analysis of blister control at 6 weeks. The results of this post-hoc analysis are
shown in Table 48. This shows that the non-inferiority status of doxycycline was robust to excluding those
who used additional topical corticosteroids in the 3 weeks prior to the 6-week blister count assessment,
at which the presence of three or fewer significant blisters was considered a treatment success.
TABLE 48 Proportions of participants who achieved treatment success at 6 weeks: PP analysis using any topical
corticosteroid use in weeks 3–6 as a reason for exclusion from the PP analysis population
Outcome
Number (%) of patients
Doxycycline Prednisolone
Success 49 (74.2) 82 (93.2)
Failure 17 (25.8) 6 (6.8)
Total 66 88
Difference in proportions (prednisolone – doxycycline) (90% CI) (%) Adjusted:a 19.3 (9.6 to 29.0)
Unadjusted: 18.9 (9.0 to 28.8)
a Estimates are from a regression model adjusted for baseline severity of BP and Karnofsky score; however, age was
omitted from the model because the model failed to converge when age was added as an adjustment factor.
Note
For the study treatment doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI
should fall below 37%. This analysis includes all patients with a blister count at week 6 and excludes those who were lost
to follow-up or who died before week 6.
0.0
0.5
0.8
0.9
1.0
109
101
76
101
61
98
54
95
52
91
52
89
Doxycycline
Prednisolone
Number at risk
0 6 13 26 39
0.4
0.6
52
Weeks from randomisation
Doxycycline
Prednisolone
FIGURE 7 Kaplan–Meier survival plot showing time to change of treatment. Note: A change in treatment refers to
a change from the allocated treatment (either doxycycline or prednisolone) to the other treatment. This graph
includes the 213 patients who formed the mITT population for the primary efficacy outcome.
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Post-hoc analysis: safety data at 52 weeks according to baseline
disease severity
To assist with interpreting the health economic analysis, an additional post-hoc analysis was performed for
the primary safety data according to baseline disease severity (Table 49).
Similar post-hoc subgroup analyses for imputed data showed similar results: the differences in the
percentages experiencing a related adverse event (prednisolone – doxycycline) were 25.2% (95% CI 4.0%
to 46.3%) for mild baseline severity, 28.6% (95% CI 9.9% to 47.3%) for moderate baseline severity and
–6.1% (95% CI –32.0% to 19.7%) for severe baseline severity.
TABLE 49 Participants reporting an adverse event of at least grade 3 that is possibly, probably or definitely related
to BP medication in the 52 weeks following randomisation (raw data)
Subgroupa
Number (%) of patients
Number (%) experiencing a
related adverse event
(from raw data) Difference in percentage
(prednisolone – doxycycline)
(95% CI)bDoxycycline Prednisolone Doxycycline Prednisolone
Mild baseline
severity
40 (33.1) 35 (31.0) 6 (15.0) 14 (40.0) 25.0 (5.4 to 44.6)
Moderate baseline
severity
47 (38.8) 43 (38.1) 5 (10.6) 17 (39.5) 28.9 (11.8 to 46.0)
Severe baseline
severity
34 (28.1) 35 (31.0) 11 (32.4) 10 (28.6) –3.8 (–25.5% to 17.9)
Total 121 113 22 (18.2) 41 (36.3) 18.1%
a Baseline severity: mild < 10 blisters; moderate 10–30 blisters; severe ≥ 31 blisters.
b Estimates are from an unadjusted regression model.
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Chapter 4 Cost-effectiveness
Objective
The objective of the economic analysis was to estimate the cost-effectiveness of doxycycline-initiated
therapy compared with that of prednisolone-initiated therapy for patients with BP from the perspective of
the English NHS.
Overview
Economic analysis is intended to inform decision-makers about the value for money of treatment
alternatives, in a context in which health-care resources are limited and prioritisation is informed, at least
in part, by the efficient use of resources.39 The economic analysis within the BLISTER trial followed a
prospectively agreed analysis plan and provides robust and unbiased evidence of cost-effectiveness,
augmenting the trial estimates of clinical effectiveness. The BLISTER trial featured a pragmatic multicentre
design reflecting real-world clinical practice and thus cost and outcome profiles are likely to reflect routine
care in NHS settings. Individual patient data collected within the BLISTER trial included NHS treatment costs
and health status, estimated as QALYs. Cost-effectiveness analysis captures the effect of treatment as
changes in costs and QALYs. Given that follow-up was limited to 1 year, no discounting of future costs
and benefits was applied.
The analysis followed ITT principles, with patients included in the analysis according to the treatment
allocated by randomisation, irrespective of subsequent care.
Because of some missing data during trial follow-up, a base-case analysis was constructed in which missing
data were imputed using multiple imputation. Supportive sensitivity analyses included only patients with
complete data, thus exploring the impact of imputation.
Methods
Data sources
Resource use and quality-of-life measurements were collected from patients by health-care professionals at
mandatory clinics at baseline and 6, 13, 26, 39 and 52 weeks. Generic health-related quality of life was
assessed using the EuroQol questionnaire (containing the EQ-5D-3L and EQ VAS). The DLQI was included
as a disease-specific quality-of-life measure.
The EQ-5D scores were converted to health status scores using the value set (time trade-off recommended
by the EuroQol group).40,41 Using the trapezoidal rule, the AUC of health status scores was calculated,
providing patient-level QALY estimates for the cost-effectiveness analysis.42 Similarly, EQ VAS and DLQI
scores were integrated discretely over time. As AUC estimates were predicted to correlate with baseline
scores (and thus potential baseline imbalances), AUC estimates were adjusted for baseline scores.43
Sensitivity analyses explored adjusted and unadjusted estimation including a range of patient covariates:
age, sex, baseline blister severity and baseline Karnofsky score as well as baseline outcome measure score.
Resource capture included use of study and non-study drugs as well as health service contacts: GP clinic
and home visits, practice and district nurse visits and outpatient visits and inpatient stays. Patients were
asked to recall use of resources since their last clinic visit and were given a diary at the beginning of the
study to aid recall. Drugs recorded related to the management of BP or its sequelae. For health service
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contacts patients were asked to identify all patient contacts as well as those related directly to the
management of BP or its sequelae. Consequently, ‘attributable costs’ are used in the base-case analysis
and a sensitivity analysis included ‘all costs’.
Unit costs of resources were estimated or drawn from national reference sources for 2013 and are shown
in Table 50. Study and non-study drugs were prescribed at varying doses. Using national PCA data,33
average costs per unit weight of therapeutic were determined and applied to patient drug use records.
The list of drugs used included a number of occasionally prescribed drugs; pragmatically, drugs that were
prescribed on more than five occasions during the course of the trial were costed. Costs for inpatient stays
(in days) and outpatient visits were estimated using Hospital Episodes Statistics (HES)36 and NHS reference
costs.35 National HES data were explored for inpatient episodes with a primary diagnosis of International
Classification of Diseases L12.0 Bullous Pemphigoid. The 10 most common Healthcare Resource Group
(HRG) HRG4+ codes associated with that diagnosis were included, accounting for 96.2% of admissions.
Per diem costs for each HRG4+ code were estimated from NHS reference costs and a volume-weighted
average cost per admission for BP was estimated allowing for mean stay and cost per day. GP clinic and
home visits, and practice and district nurse visits were costed using unit costs provided by the Personal
Social Services Research Unit (PSSRU).34 Patient costs were estimated as the sum of resources used
weighted by their reference costs. The base-case analysis included only BP-related resource use.
Multiple imputation
In any form of analysis, missing data can cause serious problems. The problem is greater than a simple loss
of statistical power as missing data may be not a random event but related to treatment and outcome.
Examples include getting better (and no longer needing care) or dying, although QALY estimates allow
for and include patients who die during follow-up. Quality-of-life measures typically feature repeated
assessments over time, which are used to construct AUC estimates. This approach is both a strength and a
weakness. With a complete-case analysis the weakness is evident: more observations may mean more
incomplete assessments and loss of one follow-up assessment means the non-inclusion of that patient.
TABLE 50 Unit costs applied to patient resource use (2013 cost base)
Resource Cost (£) Unit Source
Drug
Doxycycline 0.0015 Per mg PCA33
Prednisolone 0.0221 Per mg PCA33
Azathioprine (Imuran®, Aspen) 0.0034 Per mg PCA33
Betamethasone valerate (Betnovate®, GlaxoSmithKline UK) 0.0582 Per g PCA33
Clobetasol propionate (Dermovate®, GlaxoSmithKline UK) 0.0828 Per g PCA33
Mometasone furoate 0.1368 Per g PCA33
Clobetasone butyrate (Eumovate®, GlaxoSmithKline UK) 0.0588 Per g PCA33
Contact
Inpatient 334.22 Per day HES,36 NHS reference costs35
Outpatient 98.00 Per visit HES,36 NHS reference costs35
GP clinic 46.00 Per visit PSSRU34
GP home 92.00 Per visit PSSRU34
Practice nurse 13.34 Per visit PSSRU34
District nurse 39.00 Per visit PSSRU34
PSSRU, Personal Social Services Research Unit.
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However, repeated observations may provide (partial) assessments on more patients, allowing their
experience to be reliably imputed. The base-case analysis used multiple imputation, conducted according
to good practice guidance.44,45 A range of alternative model specifications provided sensitivity analyses.
Multiple imputation provides a method of replacing each missing value with a predicted value, potentially
permitting analysis of the entire trial sample. The process begins with reporting levels of missingness and
the missing at random (MAR) assumption is then explored in the data. The MAR assumption requires that
the probability of data being unobserved is dependent on the observed values but independent of
unobserved values. Multiple imputation provides unbiased estimates of treatment effect if data are MAR.
Additionally, complete-case analysis provides unbiased estimates only if data are missing completely at
random, that is, the probability of data being unobserved is independent of both observed and
unobserved values. The imputation model included all variables used within analysis models to preserve
correlation structures.
A regression model was used to generate multiple imputed data sets (or ‘draws’), in which missing values
were predicted drawing on predictive covariates. These included age, sex, baseline blister severity and
baseline Karnofsky score as predictors only and outcome measures (at each time point) and costs as
predictors and imputed variables. Each draw provided a complete data set that reflected the distributions
and correlations between variables. Predictive mean matching was used to enhance the plausibility and
robustness of imputed values, as normality could not be assumed. The model used fully conditional
Markov chain Monte Carlo methods (multiple imputation by chained equations), which are appropriate
when missing and correlated data occur in more than one variable. Each draw was analysed independently
and the estimates obtained were pooled to generate mean and variance estimates of costs and QALYs
using Rubin’s rule, a method that captures within and between variances for imputed samples.46 To
minimise the information loss of finite imputation sampling, 50 draws were taken.46 This resulted in a loss
of efficiency relative to infinite sampling of < 0.5% in all imputed values. The distribution of imputed and
observed values was compared to establish that imputation did not introduce bias into subsequent estimation.
Incremental analysis
The goal of economic analysis is to inform decision-makers about the incremental costs and benefits of
change; when expressed together in the cost/QALY metric this facilitates comparison with other
technology choices. The analysis reports costs, QALYs and cost per QALY comparing doxycycline-initiated
therapy with prednisolone-initiated therapy for patients with BP.
Bivariate regression using seemingly unrelated regression equations was used to model incremental
changes in costs and QALYs. This method respects the correlation of costs and outcomes within the data
and allows adjustment for a set of covariates that can be explored.47 Baseline quality-of-life scores were
included within all QALY estimation models to allow for potential baseline imbalances.38 The incremental
cost-effectiveness ratio (ICER) was estimated as the difference in mean total costs between treatments
divided by the difference in mean total QALYs. Value for money is determined by comparing the ICER
with a threshold value, typically the National Institute for Health and Care Excellence threshold of
£20,000–30,000 per QALY for UK studies. This represents the willingness to pay for an additional QALY
and lower values than the threshold could be considered cost-effective for use in the NHS. The net
monetary benefit (NMB) of changing treatment was also reported as a recalculation of the ICER at a range
of thresholds of willingness to pay for an additional QALY. The NMB succinctly describes the resource gain
(or loss) when investing in a new treatment when resources can be used elsewhere at the same threshold.48
Uncertainty
A range of decisions are made in the construction of cost-effectiveness models, for example which costs to
include, whether or not to adjust for covariates and whether or not to impute missing values. These
options are presented and the most plausible assumptions form the base-case analysis; assumptions are
explored using a range of supportive sensitivity analyses. The analyses carried out in this study are
described in Table 51.
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The imputation data set provides the most plausible base-case analyses, but a complete-case analysis and
unadjusted analysis provide useful sensitivity analyses. No method of analysis can provide protection from
bias if the assumption that data are MAR does not hold (adequately). Joint distributions of costs and
outcomes were generated using the (non-parametric) bootstrap method, with replicates used to populate
the cost-effectiveness plane and generate cost-effectiveness acceptability curves. The cost-effectiveness
acceptability curve compares the likelihood that treatments are cost-effective as the willingness-to-pay
threshold varies.49 Bootstrapping jointly resamples costs and outcomes from the original data with
replacement (maintaining the sample correlation structure) to create a new bootstrap sample from which
a change in costs and QALYs is estimated. Using bias-corrected non-parametric bootstrapping, 5000
bootstraps were taken per model evaluated. Means estimates are reported with 95% CIs.
Results
Completeness of data
Of the 253 patients included in the primary analysis of effectiveness, 220 patients (87%) had at least one
EQ-5D record during follow-up and were included in the economic analysis (Table 52). Subsequent
discussion of the completeness of the data focuses on the 220 included patients as most relevant when
considering the extent of imputation. In total, 164 patients (75%) had complete EQ-5D assessments for all
time periods. Patients who died were subsequently scored zero on visits that followed for both cost and
EQ-5D score and are included as observed data. There was a pattern of decreasing completeness as
follow-up proceeded. Cost data were complete for 191 patients (87%). It was not possible to explore
completeness of health-care costs by follow-up visit as patients could use diaries to complete missing data at a
later follow-up visit and the study drug report covered the entire follow-up period. When considering both
utilities and resource use, complete information was available for 143 patients (65%). Completeness of data
was similar when comparing treatment arms (see Table 52).
Thirty-four patients died during the trial period, 14 (10.6%) in the doxycycline arm and 20 (16.5%) in the
prednisolone arm. Missing values were imputed to provide a base-case analysis including all 220 patients.
Complete-case estimates
To describe the observed data, findings in this section are reported unadjusted for patient-level covariates.
Models in this section (Tables 53–55) are adjusted as shown in Table 51.
Mean EQ-5D scores by treatment group are reported in Table 53. There was a small non-significant
difference in health status at baseline (lower in doxycycline-initiated patients). Over the 1-year follow-up
period there were no significant differences in QALYs when comparing treatments.
TABLE 51 Base-case and sensitivity analyses
Analysis Costs Outcome Covariate adjustmenta
Base case Attributed costs, imputed EQ-5D, imputed, baseline adjusted Yes
Sensitivity analyses
1 Attributed costs, imputed EQ-5D, imputed, baseline adjusted No
2 Attributed costs, complete case EQ-5D, complete case, baseline adjusted Yes
3 Attributed costs, complete case EQ-5D, complete case, baseline adjusted No
4 All costs, imputed EQ-5D, imputed, baseline adjusted Yes
5 All costs, imputed EQ-5D, imputed, baseline adjusted No
a All models were adjusted for baseline EQ-5D score; other covariates adjusted for included age, sex, baseline blister
severity and baseline Karnofsky score.
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Resource use (in natural units) by treatment group is reported in Table 54. Predictably, study drug use for
prednisolone and doxycycline was significantly higher in patients allocated to each treatment. However,
there was significantly subsequent crossover to the alternative study drug in patients with poor outcomes.
Of patients starting on prednisolone, 12.6% subsequently received at least one prescription of doxycycline;
of patients starting on doxycycline, 57.8% subsequently received at least one prescription of prednisolone.
Patients commonly used four topical corticosteroids; the overall use of any topical steroid during the trial
was very similar for prednisolone (76.8%) and doxycycline (72.5%) patients. However, the level of use
(and steroid potency) was notably lower in the prednisolone group (average prescribed amount of all
topical steroids among users: prednisolone 121 g vs. doxycycline 277 g). Similar proportions of patients
received the immunosuppressant azathioprine (prednisolone 4.2% vs. doxycycline 8.8%) although again
TABLE 52 Completeness of data by follow-up visit
Prednisolone
(n= 108), n (%)
Doxycycline
(n= 112), n (%)
Total: analysis
(n= 220), n (%)
Total: trial
(n= 253), %
Health status
EQ-5D baseline 107 (99.1) 112 (100.0) 219 (99.5) 86.6
EQ-5D 6 weeks 102 (94.4) 108 (96.4) 210 (95.5) 83.0
EQ-5D 13 weeks 101 (93.5) 101 (90.2) 202 (91.8) 79.8
EQ-5D 26 weeks 96 (88.9) 93 (83.0) 189 (85.9) 74.7
EQ-5D 39 weeks 94 (87.0) 90 (80.4) 184 (83.6) 72.7
EQ-5D 52 weeks 92 (85.2) 90 (80.4) 182 (82.7) 71.9
EQ-5D all visits 83 (76.9) 81 (72.3) 164 (74.5) 64.8
Resource use
Drug use 95 (88.0) 102 (91.1) 197 (89.5) 77.9
Health service contacts 103 (95.4) 107 (95.5) 210 (95.5) 83.0
Costs 92 (85.2) 99 (88.4) 191 (86.8) 75.5
Health status and resource use
Costs and EQ-5D 72 (66.7) 71 (63.4) 143 (65.0) (56.5)
TABLE 53 Health status scores: complete cases
Prednisolone Doxycycline Doxycycline – prednisolonea
Mean SD Mean SD Mean 95% CI
EQ-5D baseline 0.42 0.31 0.39 0.31 –0.034 –0.117 to 0.046
EQ-5D 6 weeks 0.52 0.33 0.43 0.34 –0.094 –0.188 to –0.001
EQ-5D 13 weeks 0.51 0.33 0.42 0.37 –0.084 –0.179 to 0.013
EQ-5D 26 weeks 0.46 0.34 0.45 0.35 –0.010 –0.107 to 0.087
EQ-5D 39 weeks 0.41 0.34 0.40 0.34 –0.009 –0.106 to 0.092
EQ-5D 52 weeks 0.38 0.33 0.39 0.32 0.007 –0.091 to 0.106
EQ-5D AUC 0.46 0.30 0.42 0.30 –0.034 –0.126 to 0.057
SD, standard deviation.
a Ordinary least squares regression bootstrap-estimated means and 95% CIs.
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TABLE 54 Resource use: complete cases
Resource use
Prednisolone Doxycycline Doxycycline – prednisolonea
Mean SD Mean SD Mean 95% CI
Drug use (g)b
Prednisolonec 4.18 2.47 2.07 2.48 –2.11 –2.74 to –1.43
Doxycyclinec 1.30 5.92 16.50 18.52 15.20 11.50 to 18.97
Azathioprine 0.11 0.64 1.00 4.92 0.89 0.09 to 1.86
Betamethasone valerate 18.83 81.15 11.99 61.15 –6.84 –27.48 to 12.97
Clobetasol propionate 16.26 74.33 73.18 210.20 56.92 19.27 to 103.59
Mometasone furoate 46.63 58.21 83.37 150.4 36.74 7.72 to 66.49
Clobetasone butyrate 0.65 6.77 14.2 128.7 13.5 –1.0 to 44.7
NHS contacts (all)b
Inpatient days 7.77 22.44 8.09 22.27 0.32 –5.59 to 6.1
Outpatient visits 2.58 3.43 2.57 4.07 –0.01 –1.02 to 1.04
GP clinic visits 2.70 3.32 1.96 3.20 –0.74 –1.63 to 0.12
GP home visits 1.11 2.47 0.81 1.51 0.30 –0.89 to 0.24
Practice nurse visits 2.38 7.61 8.52 65.39 6.14 –1.48 to 19.7
District nurse visits 6.59 13.14 15.21 43.24 8.62 1.62 to 16.87
NHS contacts (attributed to BP)b
Inpatient days 3.30 8.75 5.14 12.53 1.84 –0.9 to 4.7
Outpatient visits 0.87 1.61 1.64 3.12 0.77 0.14 to 1.44
GP clinic visits 0.81 1.61 0.64 1.79 –0.17 –0.61 to 0.29
GP home visits 0.38 1.24 0.30 0.95 –0.08 –0.39 to 0.22
Practice nurse visits 1.05 6.27 1.77 7.61 0.72 –1.19 to 2.75
District nurse visits 4.60 10.26 10.57 39.73 5.97 –0.02 to 13.75
SD, standard deviation.
a Ordinary least squares regression bootstrap-estimated means and 95% CIs.
b For numbers contributing to each category see Table 52.
c Study drugs; other drugs listed are frequently used non-study drugs.
TABLE 55 Costs: complete cases (£, 2013)
Cost item
Prednisolone (£) Doxycycline (£) Doxycycline – prednisolone (£)a
Mean SD Mean SD Mean 95% CI
Study drugs 106 49 77 53 –29 –42 to –15
Non-study drugs 10 12 25 41 15 7 to 23
Study and non-study drugs 116 53 102 73 –14 –31 to 3
NHS contacts, all 3364 7574 3827 7863 463 –1591 to 2501
NHS contacts, attributed 1454 3044 2371 4822 917 –109 to 1990
Total, allb 3657 7953 3987 8120 330 –1904 to 2546
Total, attributedb 1687 3197 2455 4945 768 –318 to 1911
SD, standard deviation.
a Ordinary least squares regression bootstrap-estimated means and 95% CIs.
b Costs of drugs and care had different missing values; overall cost is not a simple sum of these items.
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the quantity of prescribed use was far lower in the prednisolone group (average prescribed amount among
users: prednisolone 2.9 g vs. doxycycline 12.4 g).
Although resource-use comparisons (attributed to BP) were generally not statistically significant, there was
a pattern of greater care received by doxycycline patients, consistent with a lower level of clinical
effectiveness reflected (by design) in the primary outcome.
Patterns of resource use were costed using national reference values (see Table 50) and are reported in
Table 55. Although costs for patients starting on doxycycline treatment appeared greater over 1 year,
the increase was not statistically significant.
Cost-effectiveness analysis
The joint distribution of incremental cost and outcome for the base-case analysis is shown graphically in
Figure 8. Patients allocated initially to doxycycline experienced a slightly lower average quality of life (–0.024
QALYs, 95% CI –0.088 to 0.041) while tending to incur higher average health costs (£959, 95% CI –£24 to
£1941), although neither finding was statistically significant (Table 56). These findings are consistent with
the results of the clinical trial, which by design demonstrated a compromise between reduced effectiveness
and increased safety for doxycycline. However, there remains the suggestion that doxycycline-initiated care
may result in greater medium-term care costs, as shown by the 95% CI in Figure 8.
The likelihood of being cost-effective at different thresholds is shown in Figure 9.
Using a willingness-to-pay criterion of < £20,000 per QALY gained, there is a 4.6% probability that
doxycycline-initiated treatment is cost-effective; conversely, there is a 95.4% chance that prednisolone-initiated
therapy is cost-effective. [Note that these (one-sided) model probabilities should not be compared with
inferential findings from (two-sided) statistical tests reported in Chapter 3.]
The NMB associated with doxycycline-initiated treatment was found to be negative and diminished with
willingness to pay (Figure 10). Using a willingness-to-pay criterion of < £20,000 per QALY gained, the
NMB associated with doxycycline-initiated therapy was negative but failed to reach statistical significance
(–£1432, 95% CI –£3094 to £230). Although statistically imprecise, analysis of the NMB suggests that
resources displaced in the NHS by doxycycline-initiated therapy would be greater than the value of
benefit gained.
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FIGURE 8 Cost-effectiveness plane: base-case analysis [cost per QALY (£), 2013].
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Sensitivity and subgroup analyses
Comparing mean costs and QALY estimates using different modelling assumptions supports the base-case
finding (see Table 56). The qualitative similarity of NMB estimates comparing imputed and complete-case
analysis, covariate adjustment and range of costs included supports the validity of the imputation process
and assumptions.
There was no interaction between treatment effect and trial stratifying variables, except in the case of blister
severity. Patients recruited with severe blisters demonstrated a different cost and outcome pattern from
patients with mild or moderate blisters, as shown in Table 56 and Figures 9 and 11. For patients presenting
with mild or moderate blisters, differences in costs and QALYs are very small and thus the costs and outcomes
can be thought to be similar. For patients presenting with severe blisters, doxycycline-initiated treatment
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FIGURE 9 Cost-effectiveness acceptability curve: base-case analysis – doxycycline-initiated therapy.
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FIGURE 10 Relationship between net monetary benefit and willingness to pay for doxycycline-initiated treatment.
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presents greater costs (£2558, 95% CI –£82 to £5198) and poorer quality of life (–0.090 QALYs, 95% CI
–0.222 to 0.042), which together make this strategy appear a poor investment (NMB –£4361, 95% CI
–£8283 to –£439) using a willingness-to-pay criterion of < £20,000 per QALY gained.
Other quality-of-life measures
Additionally, EQ VAS and DLQI scores were used to derive AUC scores over the course of the 1-year
follow-up period (Table 57).
The EQ VAS is scored from 1 to 100; equivalent QALY scores are obtained by dividing by 100, although
the EQ VAS is not recommended for QALY estimation within trials as values are self-rated rather than
societal. As with the EQ-5D estimates, there was no significant difference between treatments. DLQI
estimates were significantly higher (denoting a poor outcome for doxycycline-initiated therapy).
Being a disease-specific quality-of-life measure, the DLQI is potentially more sensitive to change than a
generic measure; nonetheless, the changes correspond to an average of 1 point on a 30-point scale and
are of uncertain clinical importance.
Conclusion
Patient-level data from the BLISTER trial provide the most robust evidence to date on whether or not
doxycycline-initiated therapy is cost-effective as a treatment for patients with BP. The trial is concerned
with the comparative short-term healing and long-term safety of doxycycline and prednisolone.
Summatively, the profile of EQ-5D scores draws together the short-term and long-term patterns
(see Table 52). A small quality-of-life benefit for prednisolone may occur in the first few months but would
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FIGURE 11 Cost-effectiveness plane: subgroup analysis [cost per QALY (£), 2013].
TABLE 57 EuroQol visual analogue scale and DLQI AUC estimates
Analysis Incremental cost (95% CI) (£) Incremental outcome (95% CI)
EQ VAS, imputed, covariate adjusted 804 (–177 to 1785) 0.005 (–5.138 to 5.147)
EQ VAS, imputed, baseline adjusted 808 (–248 to 1864) –0.555 (–5.874 to 4.764)
DLQI, imputed, covariate adjusted 841 (–144 to 1826) 1.162 (0.376 to 1.948)
DLQI, imputed, baseline adjusted 832 (–228 to 1892) 1.162 (0.376 to 1.948)
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disappear by 6 months. Hence, although an extrapolation exercise was originally planned as part of the
economic analysis, with modelling beyond 12 months, there was no rationale to pursue this.
In the base-case analysis (using multiple imputation) similar costs and outcomes were found regardless of
whether patients received doxycycline-initiated therapy or prednisolone-initiated therapy. The joint
distribution of costs and QALYs nonetheless suggests that doxycycline-initiated therapy may not be
cost-effective. However, this finding seems to have been driven by the performance of the subgroup of
patients with severe blisters. For patients presenting with mild or moderate blisters the economic and
clinical findings align; given similar costs and outcomes, treatment decisions should be patient led and
informed by the different profile of the two drugs. The clinical and economic findings for patients with
severe blisters are different from the findings for those with moderate and mild disease. The economic
analysis provides a clear preference for prednisolone-initiated therapy for patients presenting with severe
blisters. This finding is returned to in the discussion (see Chapter 5).
The findings were robust to a range of sensitivity analyses using the complete-case data set; all rather than
attributed costs; and different levels of model adjustment.
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Chapter 5 Discussion
Main findings
This pragmatic study suggests that a strategy of starting people with BP on 200 mg/day of oral doxycycline
is significantly safer over the course of a year than a strategy of starting with oral prednisolone (0.5 mg/kg/day).
These long-term gains in safety for doxycycline are at the expense of short-term compromises in effectiveness
in terms of blister control at 6 weeks, as we had anticipated. Both of our primary end points in this study
supported our a priori hypothesis of non-inferiority of short-term blister control and superiority of safety for
doxycycline compared with prednisolone, and these findings were robust to ITT and PP analysis and a range of
sensitivity analyses.
Although the time point for assessing our primary outcome of short-term control of blisters was at
6 weeks, the non-inferiority of doxycycline compared with prednisolone was maintained within our
prespecified margin when assessed at 13 and 52 weeks.
Treatment success was defined as having three or fewer significant blisters remaining, rather than
complete clearance. There was a greater difference between the groups when the proportions of patients
who were completely blister free were compared, but, in clinical practice, treatment is usually considered
successful when only a few blisters remain because achieving complete clearance risks potentially
‘overtreating’ the patient.
Given that untreated BP tends to get worse, the study has also produced compelling new evidence that
doxycycline does produce a genuine clinical effect in controlling blisters in BP. How tetracyclines, such
as doxycycline, work in BP is still unclear, but it is suggested that they may exert an anti-inflammatory
effect by inhibiting chemotaxis of neutrophils and eosinophils and blocking certain metalloproteinases.26
The study also shows that oral prednisolone at a dose of 0.5 mg/kg/day (rather than a higher dose of
1 mg/kg/day) is very effective in controlling blisters for mild and moderately severe BP, with response rates
of 97% and 98%, respectively, and provides a clinically useful response rate of 75% for those with severe
disease, an evidence gap that has been highlighted in previous guidelines.15 Corresponding response rates
for doxycycline for mild, moderate and severe disease were 76%, 78% and 66%, respectively – still
clinically useful given the potential long-terms reduction in adverse effects compared with prednisolone.
It should be noted, however, that, although there was a suggestion of less difference between the two
treatment strategies in those with severe baseline blisters, we did not find any statistical evidence that the
differences in response rates between prednisolone and doxycycline varied according to baseline disease
severity according to our planned interaction tests (see Tables 9, 19 and 20).
All safety outcomes pointed in the same direction, showing that is a safer to embark on a strategy
of starting patients with BP on doxycycline rather than prednisolone. There were fewer severe,
life-threatening or fatal treatment-related adverse events in those started on doxycycline and analysis of
all-cause mortality showed that there were fewer deaths, both total and treatment related, in the
doxycycline group. The overall differences between the groups are likely to be larger if higher doses of oral
prednisolone are used, such as 0.75 mg/kg/day, as recommended in recent guidelines.15 The safety
advantage of doxycycline-initiated treatment appeared to be lost in those with severe disease at baseline in
a post-hoc analysis (see Table 49). Overall adverse events (including mild and moderate) were similar in
both groups, however, and quite high overall (> 80%) and mainly in keeping with the known adverse
event profile for each drug. Nuisance adverse events such as nausea were higher in the first 6 weeks of
treatment with doxycycline, which might have accounted for a greater lack of adherence to this treatment
policy (see Table 6) compared with prednisolone.
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
51
Patients were able to switch treatments in this pragmatic study, which meant that some of the short-term
effectiveness at 6 weeks of a strategy of starting with doxycycline could be attributed to oral prednisolone
and, conversely, some of the severe, life-threatening and fatal events at 1 year in the doxycycline group
could be attributed to those patients who switched to oral prednisolone. It is important therefore to be
aware of the pragmatic perspective of this study, that is, to test the strategy of starting a patient with BP
on doxycycline rather than a policy of starting with oral prednisolone. Although there was a considerable
degree of switching, differences between the groups were clear throughout the study. At 6 weeks there
was no switching in the prednisolone group but approximately one-quarter of those started on doxycycline
had switched treatment. By 52 weeks approximately half of those who started on doxycycline had
switched treatment compared with only approximately 10% of those who started on prednisolone. If all
patients started on doxycycline switched to oral prednisolone it is likely that there would be no difference
in effectiveness and safety.
The quality of life of patients in both groups improved over time and there were only small differences
between the groups by 52 weeks. Although both groups showed a similar improvement in quality of life,
as measured by the skin-specific DLQI, the prednisolone group improved more rapidly than the doxycycline
group, probably reflecting the more rapid onset of blister control for those taking oral prednisolone.
Cost-effectiveness
Patient-level data from the BLISTER trial provide the most robust evidence to date on whether or not
doxycycline-initiated therapy is cost-effective as a treatment for patients with BP. The base-case analysis
(using multiple imputation) found similar costs and outcomes regardless of whether patients received
doxycycline-initiated therapy or prednisolone-initiated therapy. The joint distribution of costs and QALYs
nonetheless suggests that doxycycline-initiated therapy may not be cost-effective, with only a 4.6%
probability of doxycycline being more cost-effective than prednisolone if societal willingness to pay is
capped at £20,000 per QALY. However, post-hoc subgroup analysis of patients with and without severe
blisters produced discrepant findings. For patients presenting with mild or moderate blisters the economic
and clinical findings align. Prednisolone- and doxycycline-initiated treatments result in similar costs and
outcomes and thus treatment decisions should be patient led and informed by the different profiles of the
two drugs. It should be noted that both drugs are inexpensive and widely available worldwide. From a
health policy point of view, the clinical and economic analyses both show some variation in findings for
patients with severe blisters at baseline; on the grounds of cost-effectiveness there is a clear preference for
prednisolone-initiated therapy for those with severe disease.
How our evidence fits with existing evidence
The 2010 Cochrane review on interventions for BP21 found that combination treatment with tetracycline
and nicotinamide may be effective, but this was based on only one small and inadequately reported trial.
Because tetracyclines are widely used in practice, it was concluded that this treatment option needs further
investigation. No further trials of tetracyclines were identified in a subsequent systematic review23 nor in a
search of the Cochrane Central Register of Controlled Trials database using ‘pemphigoid’ as a search term
(28 May 2015).
Guidelines for the management of BP produced by the British Association of Dermatologists in 201214
discuss the use of potent topical corticosteroids over the entire body (except the face), as these have been
shown to be effective and much safer than oral steroids.18 Potent topical steroids are associated with some
adverse effects, such as thinning of the skin and easy bruising. The risk of experiencing adverse effects
from use of topical steroids depends on the strength of the steroid, how long it is used for, which area of
the body it is applied to and the kind of skin problem; if a high-strength, potent steroid is used, enough
may be absorbed through the skin to cause systemic adverse effects such as adrenal insufficiency or
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Cushing syndrome. For those patients for whom applying topical corticosteroids is not practical, oral
steroids are the main recommended systemic medications. Oral steroids are effective in the treatment of BP;
however, common adverse effects of oral steroids include weight gain, diabetes, infections, fractures and high
blood pressure. The British guidelines recommend oral prednisolone at doses varying from 0.3 mg/kg/day to
1 mg/kg/day, depending on disease severity.14 Spanish guidelines from 2014 recommended oral prednisolone
at doses of 0.5–0.75 mg/kg/day26 and the same doses were recommended in guidelines produced by the
European Dermatology Forum in 2015.15 All three guidelines mention tetracyclines as a possible treatment for
BP and point to the need for further high-quality evidence for tetracyclines.
The BLISTER study has now addressed the recommendation in the Cochrane 2010 review and a range of
guidelines to further investigate the effects of tetracyclines in patients with BP, confirming its modest
effectiveness and superior safety compared with oral prednisolone at a dose of 0.5 mg/kg/day.
Strengths and limitations
Strengths
This was a large, multicentre, multinational trial of 253 evaluable participants that had the power to detect
clinically important differences. The trial had good external validity as patients were recruited from a large
number of hospitals all over the UK and Germany, covering those with all types of disease severity, and
from a range of hospital settings and socioeconomic areas. Additionally, patients were not excluded on the
grounds of comorbidities and any patient with active BP was eligible. With the exception of incapacity to
consent, patients were excluded only on safety grounds. Typically, BP patients are elderly and present with
several comorbidities and so inclusion of such a population as in this study was an important issue.
This trial was designed to reflect clinical practice as far as possible, making the results useful in the real-life
setting of a dermatology clinic. We assessed the degree to which the study was pragmatic using the
pragmatic–explanatory continuum indicator summary tool25 and concluded that the trial was more
pragmatic than explanatory.
There is no evidence of selection bias as the two groups were well matched for all baseline characteristics.
Allocation of treatment was concealed by blinding the investigator until the 6-week blister count had been
carried out (primary effectiveness outcome). Treatment allocation was revealed only once the blister count
was entered into the trial database, thereby minimising the potential for performance and information
bias. The investigator was unblinded for the remaining assessments for that participant, for example the
primary safety outcome (adverse events over the full 52 weeks), as the investigator was often also the
treating physician for this trial and it was not feasible to have a second (blinded) outcome assessor to
collect adverse event data at every recruiting site. A relatively objective measure (adverse events graded
according to the Common Terminology Criteria for Adverse Events) was chosen to minimise bias for the
primary safety outcome measure.
As the investigator was blinded for the first 6 weeks of treatment (until the primary effectiveness outcome
had been assessed), it was difficult for local investigators to comment on the relatedness of adverse events.
Therefore, an independent adjudicator judged the relatedness of any adverse events to trial medication so
that the blinding of the investigator for the primary effectiveness outcome could be maintained. In
addition, all severe, life-threatening and fatal adverse events were independently assessed for relatedness
to the trial medication to ensure that relatedness was being properly attributed.
The primary effectiveness results were similar in both the ITT population and the PP population. This is
particularly important in this trial because of the non-inferiority comparisons, in which dependence on
the ITT population alone risks falsely concluding a lack of difference between groups when there are
significant amounts of missing data.50 Similarly, findings from the cost-effectiveness analysis were robust to
a range of sensitivity analyses, providing confidence in the modelling assumptions.
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To minimise selective reporting bias, the trial was registered before recruitment started, the protocol
published and the statistical analysis plan made freely available on the trial website [see https://ctsu.
nottingham.ac.uk/ts0614/summary.asp (accessed 12 November 2015)]. All planned outcomes and analyses
are reported here and any post-hoc analyses have been clearly indicated as such.
Limitations
This trial was a comparison between initiating treatment with doxycycline and initiating treatment with
prednisolone rather than an explanatory trial evaluating the pharmacological effects of these treatments.
It is very likely therefore that some of the treatment response in patients who switched from initial
doxycycline treatment to prednisolone can be attributed to prednisolone. Despite treatment switches, there
were still fewer medically serious side effects in those starting on doxycycline than in those starting on
prednisolone over the course of 1 year. The strategy of initiating treatment with doxycycline and thus
reducing the overall dose of corticosteroids is a safer treatment approach than starting on prednisolone
over the course of 1 year.
To reflect clinical practice in which topical corticosteroids are often used early on in addition to systemic
treatments,14 the use of potent topical corticosteroids applied only to blisters was permitted for the first
3 weeks. A washout period from week 3 to week 6 allowed a clearer assessment of the effectiveness of
doxycycline at 6 weeks. It is unlikely therefore that topical corticosteroid use only in the first 3 weeks
of treatment was responsible for the blister control observed at 6 weeks, given such a substantial 3-week
washout period that followed.51 More participants in the doxycycline group had to use potent topical
corticosteroids during the washout period, although the non-inferiority findings for the primary
effectiveness outcomes were robust to excluding such participants in a sensitivity analysis. Localised use
of topical corticosteroids was permitted after week 6 when needed to reflect clinical practice and so
assessments at all other time points could be affected to some degree by such usage.
The prespecified non-inferiority margin for effectiveness was relatively wide (with an upper CI of 37%),
resulting in an effectiveness estimate for doxycycline that was both non-inferior and inferior compared
with the prednisolone strategy, a paradox that was anticipated beforehand.52 When surveyed prior to the
trial starting (see Appendix 1), there was clearly a willingness among UK dermatologists to accept a
considerable reduction in short-term effectiveness of doxycycline for a treatment that did not result in such
severe long-term side effects.
There was a relatively high dropout rate in this trial, reflecting the multiple morbidities and frailty of a
mainly elderly study population, with the potential for differential reporting bias. A low dropout rate of no
more than 5% was predicted for the week 6 visit given the morbidity of the disease, but the dropout rate
was higher than anticipated (although it should be noted that 2.8% dropped out as a result of death).
There was a gradual loss over time resulting in a higher dropout rate than the 20% at 52 weeks allowed
for in the sample size calculation.
It is unlikely that the success of both treatments at 6 weeks is a result of regression to the mean, reflecting
the natural progression of the disease, because BP is a progressive disease.53,54 Additionally, there is
evidence that very low doses of prednisolone (0.3 mg/kg/day) are not effective,55 suggesting that there is
little evidence to support a placebo effect. Even if one postulates a placebo/natural resolution response of
around 20% at 6 weeks, the study response rates for effectiveness at 6 weeks (74.4% and 92.3% for
doxycycline and prednisolone, respectively) are much higher and are likely to represent a true therapeutic
response. Including a third placebo arm would have been unethical and would have probably failed
to recruit.
As we collected data only on adverse events that were deemed to be possibly, probably or definitely
related to the study treatment, the side effects of which are well known, it is possible that some degree of
attribution bias could have occurred, for example sepsis occurring in a patient taking oral prednisolone
might have been more likely to have been attributed to the drug rather than being recorded as a natural
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event. We think that this is unlikely because it was expected that the rate of severe adverse effects would
be higher in the prednisolone group, based on knowledge from other trials,18 and because the number of
deaths (regardless of attribution) was higher in the prednisolone group. Mild and moderate treatment-related
adverse events for both drugs were fairly similar between groups, with grade 3 and above adverse events
more common in the prednisolone group (see Table 32), arguing against a differential bias towards attributing
more events to prednisolone. Determining the true attribution of adverse events to drugs is difficult in
clinical practice and all unclear grade 3, 4 and 5 events in this trial were reviewed by a senior independent
dermatologist who had access to the medical backgrounds of study participants and the chronology of events.
In the absence of data on all adverse events, which was deemed unnecessary by the regulatory authorities for
two such study drugs with well-established adverse effect profiles, some degree of attribution bias could have
occurred in this study, but in a way that reflects how such attribution would be judged in everyday clinical
practice, as per the pragmatic design of the study.
The generalisability of these results may be reduced by not including patients with dementia. Such patients
were not included, as ethics committees insist that people with dementia, the majority of whom are
unable to give informed consent, should not be recruited into trials if a trial can be delivered without
involving such patients. However, in a disease that affects mainly the elderly, a large part of the patient
population will be affected by dementia. It is unclear, though, whether or not having dementia would be
likely to affect the treatment comparisons described in this study, as issues such as adherence are likely to
have been similar in both groups. It is also worth noting that large numbers of potentially eligible new
cases of BP for our study ended up not being eligible because their GP had already started them on
oral prednisolone.
Although relapse rates were assessed, the results should be interpreted with some caution. To make it
practical for clinicians in busy clinics to be able to include patients in this trial, they had to decide only
whether or not the patient had < 4 significant blisters at each blister count (other than baseline), rather
than undertake the time-consuming process of carrying out a full blister count. This means that it is
possible that a patient who was considered a treatment success because of the presence of only two
significant blisters could then ‘relapse’ by having just four at the next visit. Other patients may go from
being almost blister free to having ≥ 30 blisters, which might be considered a more ‘true’ relapse.
However, our relapse definition does give some indication of relapse rates and the direction is reflective of
the other effectiveness outcomes in the trial.
All economic analyses in modelling the bivariate distribution of costs and QALYs involve assumptions.
For example, judgements are made about the base-case model, the estimation method, adjustment for
covariates, attribution of resource use and unit costs applied, as well as the quality-of-life measure used
and societal weighting applied. As levels of missing data increase, complete-case analyses become
progressively less satisfactory, whereas multiple imputation inevitably requires strong assumptions about
data being MAR, which are only partially testable. Careful consideration of modelling issues and use of
sensitivity analyses, exploring assumptions, provide some indication of the robustness of findings.
Patient and public involvement was not as strong as it could have been in this study. We failed to identify
patients with BP or their carers who were willing to join our study team, despite repeated requests across study
sites. Most patients were elderly and infirm and not able to travel to team meetings and no patient support
group exists for BP that we could tap into. Perhaps we did not try hard enough. We did manage to find a
patient and a carer who kindly joined the independent Trial Steering Group, one of whom (Penny Standen)
was able to advise the team on the interpretation of the study. She also helped to write the plain English
summary once the study was completed. Further qualitative work with patients to explore their views on the
trade-off between short-term blister control and long-term safety gains would be worthwhile.
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
Implications for practice
This was a pragmatic trial, designed to be relevant to the sorts of people with BP typically seen in
secondary care. All suitable patients who gave consent were included and the use of localised topical
corticosteroids was allowed in the initial few weeks of the trial, along with the ability to change the
treatment and the dose as required during the trial.
Some clinicians expressed the view at the study outset that doxycycline, if effective at all, would be useful
only in those with mild disease, an assertion not borne out by this study. We found no evidence that the
difference in short-term effectiveness between the two treatment strategies was dependent on the
baseline disease severity. Higher absolute response rates for mild to moderate disease were seen for both
treatment policies, but even those with severe disease had a clinically useful response at 6 weeks
(75% and 66% treatment success at 6 weeks for prednisolone and doxycycline respectively). In terms of
short-term effectiveness, the policy of starting treatment with doxycycline appears to be a potentially
useful approach for patients with all severities of BP. With regard to serious related adverse effects, most
of the advantage of doxycycline-initiated therapy resided in the mild and moderate severity groups, and
cost-effectiveness analysis suggests that doxycycline-initiated therapy is not cost-effective in those with
severe disease at baseline. BP is a disease associated with significant morbidity and mortality and the
possible harms of treatment need to be given more attention.
The work by Joly et al.18 shows that whole-body application of topical corticosteroids is a good treatment
strategy for BP. However, such an approach is not always practical: very elderly or immobile patients would
need considerable additional support to be able to apply a cream all over their body every day, and in
many clinical settings this is not available. This study has suggested that initiating treatment with oral
doxycycline is an effective and safe treatment and so, when application of topical corticosteroids is not a
practical option, doxycycline may be offered as a safer alternative to oral corticosteroids whenever possible.
It is important that patients understand the trade-off between doxycycline and prednisolone. Starting on
doxycycline may mean that symptoms last longer than if starting on oral prednisolone and they may
experience more mild side effects such as gastrointestinal problems, but they are less likely to experience
severe and life-threatening side effects, even if they have to eventually switch to oral prednisolone.
In circumstances in which treatment with oral prednisolone is still indicated, these results have
demonstrated that, although not as safe as doxycycline, a dose of 0.5 mg/kg/day probably produces a
clinically worthwhile treatment response that is comparable to that seen with higher doses such as
1.0 mg/kg/day mentioned in guidelines,15 even for those with severe disease.
Implications for research
Qualitative work exploring patients’ views on the trade-off between short-term blister control and
long-term safety might also be worthwhile, perhaps accompanied by a patient decision aid. Follow-up
surveys of the clinicians from the UK Dermatology Clinical Trials Network who took part in determining
the initial non-inferiority margin might also be useful to see whether or not the results have changed
their practice.
It is clear from the results presented here that reducing the total amount of prednisolone, even if it is not
avoided altogether, was beneficial to patients. Therefore, it would be useful to evaluate in a clinical trial
whether a strategy of initiating treatment with prednisolone to achieve early disease control followed by a
switch to maintenance therapy with doxycycline is safer than maintenance therapy with a reducing dose
of prednisolone.
In the absence of a placebo-controlled study of doxycycline in BP, some might argue that such a study
should be carried out, perhaps for mild disease and for a short duration of 6 weeks. We think that such a
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study would be unethical, given that the high response rates for doxycycline seen in this study (74% at
6 weeks) are likely to be much higher than any placebo or natural regression effects for what is thought to
be a persistent and progressive disease in most people.
It might also be useful to investigate whether or not other antibiotics such as lymecycline, which are
reported to have fewer side effects than doxycycline, are also beneficial in BP. Although doxycycline was
far safer than prednisolone with respect to severe and life-threatening side effects, there was a high
number of mild and moderately severe side effects with doxycycline, which are a nuisance to people taking
long-term medicines. Inclusion of patients with dementia may also be considered in future studies, as they
may respond to treatments differently.
A range of other systemic treatments such as azathioprine, methotrexate, dapsone, mycophenolate,
high-dose intravenous immunoglobulin, plasmapheresis or rituximab have been used for BP that is more
severe or unresponsive to first-line treatments such as topical or oral corticosteroids, but, apart from some
combination therapies,56 most have been poorly evaluated. As this study has indicated how conclusions
may differ for those with severe disease, future trials should present results according to baseline severity
and consider planned subgroup analyses for those with severe disease. Consideration should be given
to adopting clearer definitions of remission and early, intermediate and late observation points as
recommended in 2012 by an international group.57 There is also scope for establishing a core outcome set
for future clinical trials of pemphigoid which includes outcomes that are important to patients so that the
results of new trials can be compared in meta-analysis.
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Chapter 6 Conclusions
This study has shown that a strategy of starting people with BP on doxycycline at a dose of 200 mg/dayis safer than standard oral treatment with prednisolone at a dose of 0.5 mg/kg/day over the course
of a year. Blister control with doxycycline in the first 6 weeks of treatment is inferior to that of oral
prednisolone but it is still reasonably effective and was well within our prespecified non-inferiority margin.
Overall, there is no significant difference in cost-effectiveness between the two treatment strategies
although doxycycline-initiated therapy may not be cost-effective for those with severe baseline disease.
The combined analysis of short-term effectiveness and long-term safety in this study provides critical
information for clinicians to share with patients in a shared decision-making model, as well as providing
reliable data to inform national and international guidelines, especially for those patients in whom
extensive daily application of topical corticosteroids is not feasible. Further research may consider the
evaluation of oral doxycycline to maintain remission in those who have initially been brought under rapid
control with topical or oral corticosteroids.
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Appendix 1 Survey results
Q1: What reduction in effectiveness would be acceptable?
(a) Assuming the mortality rate with oxytetracycline is 1% less than with prednisolone and prednisolone is
95% effective:
¢ a minimum median effectiveness rate of 50% would be required for oxytetracycline to have any
place in the management of BP
¢ a minimum median effectiveness rate of 80% would be required oxytetracycline to have potential
as primary treatment for BP.
(b) Assuming the mortality rate with oxytetracycline is 10% less than with prednisolone and prednisolone
is 95% effective:
¢ a minimum median effectiveness rate of 40% would be required for oxytetracycline to have any
place in the management of BP
¢ a minimum median effectiveness rate of 70% would be required oxytetracycline to have potential
as primary treatment for BP.
Q2: What reduction in mortality would be useful?
(a) Assuming oxytetracycline is 5% less effective than prednisolone and the mortality rate of prednisolone
is 40%:
¢ a maximum median mortality rate of 35% would be acceptable for oxytetracycline to have any
place in the management of BP
¢ a maximum median mortality rate of 23% would be acceptable for oxytetracycline to have
potential as primary treatment for BP.
(b) Assuming oxytetracycline is 10% less effective than prednisolone and the mortality rate of
prednisolone is 40%:
¢ a maximum median mortality rate of 30% would be acceptable for oxytetracycline to have any
place in the management of BP
¢ a maximum median mortality rate of 20% would be acceptable for oxytetracycline to have
potential as primary treatment for BP.
(c) Assuming oxytetracycline is 20% less effective than prednisolone and the mortality rate of
prednisolone is 40%:
¢ a maximum median mortality rate of 30% would be acceptable for oxytetracycline to have any
place in the management of BP
¢ a maximum median mortality rate of 15% would be acceptable for oxytetracycline to have
potential as primary treatment for BP.
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Recruitment feasibility
Question Averages
Approximately how many new cases of BP do you personally see per year? 5
Approximately how many new cases of BP are seen in your whole department per year? 14
Are you interested in helping recruit patients for this study? (approximately two patients per year,
followed up for 1 year each)
Most yes
Do you think that it would be feasible for your colleagues to refer patients to you for this study? Most yes
If yes, what proportion of the total number of BP patients presenting to your department would you be
able to get referred to you for the study?
Approximately
half
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Appendix 2 Health economics analysis plan
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Appendix 3 Reasons for exclusion from the
per-protocol analyses
TABLE 58 Reasons for exclusion from the primary efficacy analysis at week 6
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment during weeks 0–6 1 0
Changed treatment or added a new treatment to the allocated treatment 17 3
Used topical steroids between weeks 3 and 6 7 3
Missed more than 3 consecutive days of treatment 21 5
Total number of non-PP patients 34 10
Some participants may appear in more than one row.
TABLE 59 Reasons for exclusion from the secondary efficacy analysis at week 6
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment before week 6 1 0
Changed treatment or added a new treatment to the allocated
treatment before week 6
17 3
Used topical steroids between weeks 3 and 6 7 3
Missed more than 3 consecutive days of treatment before week 6 21 5
Total number of non-PP patients 34 10
Some participants may appear in more than one row.
TABLE 60 Reasons for exclusion from the secondary efficacy analysis at week 13
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment before week 6 1 0
Changed treatment or added a new treatment to the allocated
treatment before week 6
16 2
Used topical steroids between weeks 3 and 6 6 3
Missed more than 3 consecutive days of treatment before week 6 19 4
Missed more than 3 consecutive weeks of treatment between week 6
and week 13
2 0
Received > 30 g of topical steroids per week between week 6 and
week 13
5 0
Added systemic steroids to doxycycline (if allocated) or doxycycline or
another immunosuppressant to prednisolone (if allocated) between
week 6 and week 13
5 1
Total number of non-PP patients 36 10
Some participants may appear in more than one row.
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
TABLE 61 Reasons for exclusion from the secondary efficacy analysis at week 52
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment before week 6 1 0
Changed treatment or added a new treatment to the allocated treatment before
week 6
13 2
Used topical steroids between weeks 3 and 6 5 1
Missed more than 3 consecutive days of treatment before week 6 15 1
Missed more than 3 consecutive weeks of treatment between week 6 and week 52 2 0
Received > 30 g of topical steroids per week between week 6 and week 52 3 2
Added systemic steroids to doxycycline (if allocated) or doxycycline or another
immunosuppressant to prednisolone (if allocated) between week 6 and week 52
7 8
Total number of non-PP patients 30 11
Some participants may appear in more than one row.
TABLE 62 Reasons for exclusion from the secondary analysis of the proportion of participants who have a further
episode of BP during their participation in the study after previously being classified as a treatment success
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment before week 6 1 0
Changed treatment or added a new treatment to the allocated treatment before
week 6
16 3
Used topical steroids between weeks 3 and 6 7 3
Missed more than 3 consecutive days of treatment before week 6 21 8
Missed more than 3 consecutive weeks of treatment between week 6 and week 52 3 0
Received > 30 g of topical steroids per week between week 6 and week 52 5 2
Added systemic steroids to doxycycline (if allocated) or doxycycline or another
immunosuppressant to prednisolone (if allocated) between week 6 and week 52
7 9
Total number of non-PP patients 40 21
Some participants may appear in more than one row.
TABLE 63 Reasons for exclusion from the tertiary analysis of the proportion of participants classed as a treatment
success at week 3
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment before week 3 1 0
Changed treatment or added a new treatment to the allocated treatment before
week 3
14 2
Missed more than 3 consecutive days of treatment before week 3 10 6
Total number of non-PP patients 21 7
Some patients may appear in more than one row.
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TABLE 64 Reasons for exclusion from the tertiary analysis of the proportion of participants who achieved
treatment success at 52 weeks
Reason for exclusion Doxycycline, n Prednisolone, n
Increased the dose of the allocated treatment before week 6 1 0
Changed treatment or added a new treatment to the allocated treatment before
week 6
12 1
Used topical steroids between weeks 3 and 6 5 1
Missed more than 3 consecutive days of treatment before week 6 14 1
Missed more than 3 consecutive weeks of treatment between week 6 and week 52 2 0
Received > 30 g of topical steroids per week between week 6 and week 52 3 2
Added systemic steroids to doxycycline (if allocated) or doxycycline or another
immunosuppressant to prednisolone (if allocated) between week 6 and week 52
7 8
Total number of non-PP patients 29 10
Some patients may appear in more than one row.
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Appendix 4 Trial oversight committees
Trial Steering Committee
Independent members
l Professor Jonathan Barker (chairperson), St John’s Institute of Dermatology, Guy’s Hospital,
London, UK.
l Professor Pascal Joly (clinical expert), Hôpital Charles Nicolle, Rouen, France.
l Dr Jonathan Leonard (clinical expert), St Mary’s Hospital, London, UK.
l Ms Helena Haywood (dermatology nurse), Amersham Hospital, Amersham, UK.
Patient representatives
l Penny Standen.
l Brian Lockwood.
Non-independent members
l Professor Hywel Williams (chief investigator), Centre of Evidence Based Dermatology, University of
Nottingham, Nottingham, UK.
l Professor Fenella Wojnarowska (lead clinician), Nuffield Department of Clinical Medicine, University of
Oxford, Oxford, UK.
l Dr Gudula Kirtschig (clinical expert and co-ordinator for German sites), Centre of Evidence Based
Dermatology, University of Nottingham, Nottingham, UK.
l Professor Andrew Nunn (senior trial statistician), MRC Clinical Trials Unit at University College London,
London, UK.
l Daniel Bratton, Sunita Rehal, Tom Godec (trial statisticians), MRC Clinical Trials Unit at University
College London, London, UK.
l Dr Karen Harman (principal investigator representative), University Hospitals Leicester, Dermatology
Department, Leicester Royal Infirmary, Leicester, UK.
l Dr Phillip Hampton (principal investigator representative), Royal Victoria Infirmary, Newcastle, UK.
l Dr Joanne Chalmers (research fellow), Centre of Evidence Based Dermatology, University of
Nottingham, Nottingham, UK.
The current trial manager was also a non-independent member of the Trial Steering Committee.
Trial Management Group
l Professor Hywel Williams (chief investigator), Centre of Evidence Based Dermatology, University of
Nottingham, Nottingham, UK.
l Professor Fenella Wojnarowska (lead clinician), Nuffield Department of Clinical Medicine, University of
Oxford, Oxford, UK.
l Dr Gudula Kirtschig (clinical expert and co-ordinator for European sites), Centre of Evidence Based
Dermatology, University of Nottingham, Nottingham, UK.
l Professor Andrew Nunn (senior trial statistician), MRC Clinical Trials Unit at University College London,
London, UK.
l Daniel Bratton, Sunita Rehal, Thomas R Godec (trial statisticians), MRC Clinical Trials Unit at University
College London, London, UK.
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l Professor James Mason (health economist), Durham University, School of Medicine, Pharmacy and
Health, Stockton-on-Tees, UK.
The current trial manager was also a member of the Trial Management Group.
Data Monitoring Committee
l Professor S Lamb (chairperson), Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
l Dr R Graham-Brown (independent member), Department of Dermatology, Leicester Royal Infirmary,
Leicester, UK
l Dr Tracey Young (independent member), Health Economics and Decision Science, School of Health and
Related Research, University of Sheffield, Sheffield, UK.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
Appendix 5 Trial management team
A ll trial management was conducted by the NCTU, Nottingham Health Science Partners, Queen’sMedical Centre, Nottingham, UK.
Senior trial managers
l Margaret Childs.
l Diane Whitham.
Trial managers
l Caroline Onions.
l Dr Katharine Foster.
l Dr Anna Sandell.
Data managers, trial co-ordinators and administrators
l Daniel Simpkins.
l Aisha Shafayat.
l Robert Allen.
l Aimee Tooley.
l Sally Kucyj.
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Appendix 6 Recruiting centres
Recruiting group (UK) in centre number order
1. Walton Hospital, Liverpool (principal investigator: Dr A Alkali; coinvestigator: Dr G Wong; research
nurses: Ms M Harrison and Ms P Taylor).
2. Blackpool Victoria Hospital, Blackpool (principal investigator: Dr W Bottomley).
3. St Luke’s Hospital, Bradford (principal investigator: Dr A Wright; coinvestigator: Dr M Whittmann;
research nurses: Ms J Ott and Mr A Liu).
4. Brighton General Hospital, Brighton (principal investigator: Dr C DeGiovanni; coinvestigators:
Dr S Gossain, Dr S George and Dr F Imran; research nurses: Ms H Santander and Ms M Flowerdew).
5. Addenbrooke’s Hospital, Cambridge (principal investigator: Dr J Sterling; coinvestigators:
Dr J Batchelor, Dr M Chattopadhyay, Dr M Wallace, Dr G Ben-Zvi, Dr S Haque-Hussain and
Dr A Ranasinghe).
6. Sunderland Royal Infirmary, Sunderland (principal investigator: Dr S Wahie; coinvestigators:
Dr K Freeman, Dr S Nataranjan, Dr N Rajan and Dr R Ellis; research nurse: Ms A Thomson).
7. University Hospital of North Durham, Durham (principal investigator: Dr S Wahie; coinvestigators:
Dr T Sripathy, Dr V Bajaj, Dr M Vatve and Dr K Freeman; research nurse: Ms A Thomson).
8. London Road Community Hospital, Derby (principal investigator: Dr A Ferguson; research nurse:
Ms K Riches).
9. Corbett Hospital, Stourbridge, West Midlands (principal investigators: Dr I Verpetinske, Dr S Cheung;
dermatology clinical nurse specialist: Miss M Taylor).
10. Kent and Canterbury Hospital, Canterbury (principal investigator: Dr E Duarte-Williamson;
coinvestigators: Dr C Cowley, Dr E Kulakov and Dr J Mann; research nurse: Ms A Potter).
11. Frimley Park Hospital, Frimley, Surrey (principal investigator: Dr F Antony; coinvestigator: Dr J Williams;
research nurse: Ms L Moore; dermatology nurse specialist: Mrs J Herzke; clinical researcher:
Ms S Atkinson).
12. Guy’s and St Thomas’ Hospital, London (principal investigator: Dr R Groves; coinvestigator:
Dr E Benton; research nurses: Ms H Sreeneebus and Ms S Jones).
13. Harrogate District Hospital, Harrogate (principal investigator: Dr A Layton; coinvestigators:
Dr A Whitton, Dr B Walker, Dr R Strauss, Dr S Das, Dr E Marshall, Dr N Goddard, Dr L Savage,
Dr J Kwok and Dr M Walker; research nurses: Ms M Broome, Ms G Law and Mrs A Wray; clinical trials
assistant: Mrs J Hussey; research and development administrator: Mrs J Pearson).
14. Hull Royal Infirmary, Hull (principal investigator: Dr S Walton; coinvestigators: Dr R Zaman, Dr A Kapdia
and Dr V Smith; research nurses: Mr P Jones and Ms K Ashton).
15. Ipswich Hospital, Ipswich (principal investigators: Dr O Aziz, Dr S Gibbs, Dr D Rallan; research nurse:
Ms S Hood).
16. James Paget Hospital, Great Yarmouth (principal investigators: Dr I Salvary, Dr R Graham;
coinvestigator: Dr V Gajawada; research nurses: Ms S Simmons and Ms J Woods).
17. Cannock Chase Hospital, Cannock, Staffordshire (principal investigators: Dr A Azam, Dr R Rotarescu;
coinvestigator: Dr S Cheung; research nurses: Miss K Amor, Ms M Harry, Ms N Smith, Ms S Hendy,
Miss D Sirdefield and Mrs S Johnson).
18. Norfolk and Norwich University Hospital, Norwich (principal investigator: Dr N Levell; coinvestigators:
Dr N Cassie-Chetty, Dr R Coelho, Dr G Millington, Dr M McDermott, Dr A Yong and Dr M Chriba;
research nurses: Ms K Banks-Dunnell and Ms D Butcher).
19. Cumberland Infirmary, Carlisle (principal investigators: Dr N Cox and Dr M Nik; research nurse:
Ms K Gilbanks).
20. North Devon District Hospital, Barnstaple, Devon (principal investigator: Dr K Davies; research nurses:
Mr N Lawton and Ms L Wells).
DOI: 10.3310/hta21100 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 10
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Chalmers et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
83
21. Queen’s Medical Centre, Nottingham (principal investigator: Dr J English; coinvestigators: Dr M Malik,
Dr C Wooton, Dr R Murphy, Dr J Batchlor, Dr R Simpson, Dr E Burden-Teh, Dr A Yaakub and
Dr M Lam; research nurses: Ms S Davies-Jones and Ms J Llewellyn).
22. Churchill Hospital, Oxford (principal investigator: Dr V Venning; coinvestigators: Dr T McPherson and
Dr S Cooper; research nurses: Ms L Matter, Ms M Westmoreland and T McPherson).
23. Queen Elizabeth Hospital, Greenwich (principal investigator: Dr A Chapman; coinvestigators:
Dr Y Estfan and Dr N Miller; research nurse: Ms G Reeves).
24. Royal Berkshire Hospital, Reading (principal investigators: Dr G Kaushal, Dr D Seukeran, Dr I Nasr and
Dr H Malhomme; coinvestigators: Dr J Dua, Dr C Higgins, Dr A Lloyd Lavery, Dr S Ong, Dr C Allen
and Dr R Clayton; research nurses: Ms K Wilmott, Ms J Foxton, Ms J King and Ms G Grimwood).
25. Royal Devon and Exeter Hospital, Exeter (principal investigator: Dr C Bower; coinvestigators:
Dr C Charman and Dr J Varghese; research nurses: Mr R James and Ms T Hill; clinical trials
administrator: Miss M Hayward).
26. Broadgreen Hospital, Liverpool (principal investigators: Dr H Bell and Dr R Azurdia; coinvestigators:
Dr M Walsh, Dr K Ngan, Dr P Jayasekera and Dr C Angit; research nurses: Ms A Turner, Ms P Taylor,
Ms D Marsh, Ms A Young and Ms T O’Rourke).
27. Royal United Hospital, Bath (principal investigator: Dr C Lovell).
28. Sandwell General Hospital, Birmingham (principal investigator: Dr S Velangi; coinvestigators:
Dr W Szczecinska, Dr N Talsamia, Dr G Jutley, Dr M Ogboli and Dr J Halpern; research nurse: Ms T Shumba).
29. Royal Hallamshire Hospital, Sheffield (principal investigator: Professor D Gawkrodger; coinvestigators:
Dr P Cousen, Dr N Aldoori, Dr C Morgan and Dr A Diaz).
30. King’s Mill Hospital, Sutton-in-Ashfield, Nottinghamshire (principal investigator: Dr J Ravenscroft;
coinvestigators: Dr M Panchal, Dr E Bayliss, Dr J English, Dr A Yaakub and Dr H Trinh; research nurses:
Ms C Heeley and Mr A Novak).
31. Torbay Hospital, Torquay (principal investigators: Dr J Adams and Dr T Frost; research nurses:
Ms S Burns, Dr A Clepa and Dr D Benham).
32. James Cook University Hospital, Middlesbrough (principal investigator: Dr A Carmichael;
coinvestigators: Dr R Ellis, Dr A Kapadia, Dr H Reddy, Dr S Fatah and Dr J Dalrimple).
33. Warwick Hospital, Warwick (principal investigator: Dr R Charles-Holmes; coinvestigators: Dr J Carter
and Dr A Bedlow; research nurses: Ms C Jones, Ms W Seaton and Ms K Hotchkiss).
34. St George’s Hospital, London (principal investigator: Dr V Akhras; coinvestigator: Dr J Wee).
35. St Helens Hospital, St Helens (principal investigator: Dr S Winhoven; research nurse: Ms K Rutter).
36. Great Western Hospital, Swindon (principal investigators: Dr D Buckley, Dr S Gibbs; coinvestigators:
Dr L Whittam, Dr H Hempel and Dr J Gingell; research nurses: Ms S Toft and Ms J Arnold).
37. Musgrove Park Hospital, Taunton (principal investigator: Dr V Lewis; coinvestigators: Dr J Adams and
Dr R Wachsmuth).
38. Royal Victoria Infirmary, Newcastle (principal investigator: Dr P Hampton).
39. Whittington Hospital, London (principal investigator: Dr K Taghipour; coinvestigators: Dr N Kapur,
Dr R Wakeel, Dr A Friedman; research nurse: Ms L Reeves and Ms B Akworth).
40. Lincoln County Hospital, Lincoln (principal investigator: Dr K Hussain; research nurses: Ms K Horton
and Ms K Warner).
41. University Hospital, Coventry (principal investigator: Dr A Ilchyshyn; coinvestigator: Dr B Dharma;
research nurse: Ms K Hotchkiss).
42. Bristol Royal Infirmary, Bristol (principal investigator: Dr G Dunnill; coinvestigator: Dr A Bray).
43. Leicester Royal Infirmary, Leicester (principal investigators: Dr K Harmen, Dr A Alexandrov;
coinvestigators: Dr K Narayana, Dr G Johnston and Dr I Helbling; research nurses: Ms C Shelley and
Ms A Hill).
44. Weston General Hospital, Weston-super-Mare (principal investigators: Dr M Kirkup, Dr D Simmons and
Dr H Lloyd-Jones; research nurse: Mr G Saunders).
45. Whipps Cross University Hospital, London (principal investigator: Dr K Gibbon; coinvestigator:
Dr A Bewley).
46. Yeovil District Hospital, Yeovil (principal investigator: R Wachsmuth; coinvestigators: Ms F Edwards and
Dr J Boyle; research nurse: Ms M Davey).
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47. York Hospital, York (principal investigator: Dr C Lyon; research nurse: Ms J Green).
48. Aberdeen Royal Infirmary, Aberdeen (principal investigator: Dr A Ormerod; coinvestigators: Dr F Craig
and Dr F Hussain; research nurse: Ms L Lawson).
49. Royal Gwent Hospital, Newport (principal investigator: Professor A Anstey; coinvestigator: Dr J Ingram;
research nurses: Ms S Mitchell and Ms C Watkins).
50. Raigmore Hospital, Inverness (principal investigator: Dr J Vestey; coinvestigator: Ms S Halliday; research
nurses: Ms P Martin and Ms S Ross).
51. Glangwili General Hospital, Carmarthen (principal investigators: Dr D Shipley and Dr E Veysey; research
nurse: Ms A Johnson).
52. Singleton Hospital, Swansea (principal investigators: Dr E Veysey and Dr S Blackford; coinvestigator:
Dr S Sidhu; research nurse: Ms C Thomas).
53. University Hospital of Wales, Cardiff (principal investigators: Dr G Patel and Dr J Ingram;
coinvestigators: Dr R Motley, Dr A Morris, Dr C Long, Dr R Abbott, Dr M Chowdhury and
Dr S Scourfield; research nurse: Ms A Thomas).
54. Ninewells Hospital, Dundee (principal investigator: Professor J Ferguson; coinvestigators: Dr A Waters,
Dr R Dawe and Dr P Rakvit; research nurse: Ms S Yule).
Recruiting group (Germany) in centre number order
1. Universitätsklinikum Carl Gustav Carus, Dresden (principal investigators: Dr C Günther and
Professor Wozel; research nurse: Fr Blümlein).
2. Universitätsklinikum Erlangen (principal investigator: Professor M Sticherling; coinvestigator:
Dr R Renner; research nurses: Fr P Alt and Fr S Friedel).
3. Universitätsklinikum Schleswig-Holstein, Lübeck [principal investigator: Professor E Schmidt (and chief
investigator for Germany); coinvestigators: Dr D Meyersburg and Dr N Van Beek; research nurse:
Fr D Knuth-Rehr].
4. Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz (principal investigator:
Dr K Steinbrink; research nurse: Fr G Hagedorn).
5. Universitätsklinikum Münster, Münster (principal investigator: Professor Luger; coinvestigators:
Dr A Tsianakas and Dr AM Perusquia Ortiz).
6. Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg,
Würzburg (principal investigators: Professor E Broecker and Dr Benoit; coinvestigators: Dr C Hosp,
Dr J Stoevesandt, Dr D Anders and Dr H Poppe; research nurse: Fr S König).
7. Universitätsklinikum Schleswig-Holstein, Kiel (principal investigator: Professor R Gläser; coinvestigators:
Dr Rainer Hügel and Dr F Lipowsky; research nurse: Fr L Wedler).
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